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Hallmark of aging pathways
Age-related diseases
A B S T R A C T
Objective: Use of the frailty index to measure an accumulation of deﬁcits has been proven a valuable method for
identifying elderly people at risk for increased vulnerability, disease, injury, and mortality. However, com-
plementary molecular frailty biomarkers or ideally biomarker panels have not yet been identiﬁed. We conducted
a systematic search to identify biomarker candidates for a frailty biomarker panel.
Methods: Gene expression databases were searched (http://genomics.senescence.info/genes including GenAge,
AnAge, LongevityMap, CellAge, DrugAge, Digital Aging Atlas) to identify genes regulated in aging, longevity,
and age-related diseases with a focus on secreted factors or molecules detectable in body ﬂuids as potential
frailty biomarkers. Factors broadly expressed, related to several “hallmark of aging” pathways as well as used or
predicted as biomarkers in other disease settings, particularly age-related pathologies, were identiﬁed. This set of
biomarkers was further expanded according to the expertise and experience of the authors. In the next step,
biomarkers were assigned to six “hallmark of aging” pathways, namely (1) inﬂammation, (2) mitochondria and
apoptosis, (3) calcium homeostasis, (4) ﬁbrosis, (5) NMJ (neuromuscular junction) and neurons, (6) cytoskeleton
and hormones, or (7) other principles and an extensive literature search was performed for each candidate to
explore their potential and priority as frailty biomarkers.
Results: A total of 44 markers were evaluated in the seven categories listed above, and 19 were awarded a high
priority score, 22 identiﬁed as medium priority and three were low priority. In each category high and medium
priority markers were identiﬁed.
Conclusion: Biomarker panels for frailty would be of high value and better than single markers. Based on our
search we would propose a core panel of frailty biomarkers consisting of (1) CXCL10 (C-X-C motif chemokine
ligand 10), IL-6 (interleukin 6), CX3CL1 (C-X3-C motif chemokine ligand 1), (2) GDF15 (growth diﬀerentiation
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factor 15), FNDC5 (ﬁbronectin type III domain containing 5), vimentin (VIM), (3) regucalcin (RGN/SMP30),
calreticulin, (4) PLAU (plasminogen activator, urokinase), AGT (angiotensinogen), (5) BDNF (brain derived
neurotrophic factor), progranulin (PGRN), (6) α-klotho (KL), FGF23 (ﬁbroblast growth factor 23), FGF21, leptin
(LEP), (7) miRNA (micro Ribonucleic acid) panel (to be further deﬁned), AHCY (adenosylhomocysteinase) and
KRT18 (keratin 18). An expanded panel would also include (1) pentraxin (PTX3), sVCAM/ICAM (soluble vas-
cular cell adhesion molecule 1/Intercellular adhesion molecule 1), defensin α, (2) APP (amyloid beta precursor
protein), LDH (lactate dehydrogenase), (3) S100B (S100 calcium binding protein B), (4) TGFβ (transforming
growth factor beta), PAI-1 (plasminogen activator inhibitor 1), TGM2 (transglutaminase 2), (5) sRAGE (soluble
receptor for advanced glycosylation end products), HMGB1 (high mobility group box 1), C3/C1Q (complement
factor 3/1Q), ST2 (Interleukin 1 receptor like 1), agrin (AGRN), (6) IGF-1 (insulin-like growth factor 1), resistin
(RETN), adiponectin (ADIPOQ), ghrelin (GHRL), growth hormone (GH), (7) microparticle panel (to be further
deﬁned), GpnmB (glycoprotein nonmetastatic melanoma protein B) and lactoferrin (LTF). We believe that these
predicted panels need to be experimentally explored in animal models and frail cohorts in order to ascertain
their diagnostic, prognostic and therapeutic potential.
1. Introduction
The term frailty was ﬁrst mentioned in 1954 by Friend (Friend,
1954) but it was another three decades before Hays introduced the term
“frail elderly” in context of health care (Hays, 1984). In the past 20
years, research on frailty has speeded up signiﬁcantly with currently
more than 2000 publications per year (Fig. 1) and increasing interest
shown in preclinical and clinical research. Frailty is a major phenotype
of accelerated aging and describes multiorgan dysfunction or multi-
morbidity together with increased vulnerability to additional diseases
in elderly people. Frailty can be easily measured in humans by assessing
the accumulation of deﬁcits through a tool known as the frailty index
which can be used to predict response to therapies and progression of
health status and mortality. The frailty index has recently been reverse
translated to mice (Parks et al., 2012; Whitehead et al., 2014) to enable
its use in preclinical aging and multimorbidity models. Since the con-
cept of frailty has been reviewed previously (von Zglinicki et al., 2016)
we will focus our current review on the frailty biomarker concept.
Biomarkers are generally accepted to be highly valuable tools in
assessing the safety and eﬃcacy of interventions in clinical and pre-
clinical settings, but can also be used to diagnose conditions or stratify
which patients would beneﬁt most from interventions. The term bio-
marker was ﬁrst mentioned in 1989 (Gallagher and Di Giulio, 1989;
Masoro, 1989; Tunlid et al., 1989) and, interestingly, Masoro (Masoro,
1989) used the term in the context of aging research, reporting that the
“lack of knowledge concerning the nature of the primary aging pro-
cesses coupled to the lack of biomarkers of aging has made it diﬃcult to
devise fruitful approaches for the study of aging”. Since then, the un-
derstanding of the molecular and genetic pathways which are dysre-
gulated in aging and age-related diseases has increased tremendously as
has the interest in biomarkers (see Fig. 1) as a quick and quantitative
measure in all areas of biomedical research.
Given there are many frailty phenotypic measures, molecular frailty
biomarkers would be highly valuable and complementary. So far, bio-
markers for frailty have not been extensively studied (see Fig. 1) al-
though, interestingly, heart failure was the ﬁrst predicted, albeit non-
molecular marker for frailty (Rich et al., 1996), An early, rather global
description of potential soluble biomarkers of frailty, including hor-
mones, inﬂammatory markers, and nutrients, goes back to Ferrucci and
colleagues in 2002 (Ferrucci et al., 2002) which was followed by a
paper in which assessment of multiple markers was consecutively ex-
plored (Puts et al., 2005)). However, single predictive molecular mar-
kers have not been identiﬁed so far and proposed markers are often not
reproduced across various frailty cohorts or do not correlate. Given that
frailty is an age-related syndrome using the increased mechanistic un-
derstanding of aging seems an excellent tool to identify frailty markers.
Additionally, since multiple molecular pathways are involved in the
aging process and can all contribute to the various aspects of frailty, a
panel of valid biomarkers in combination with measures of frailty
would allow both diagnosis and follow up in preclinical and clinical
Fig. 1. Literature overview for the terms frailty and biomarkers. Timeline of publication mentioning biomarkers, frailty or biomarkers and frailty together. The graph
presents the ﬁrst publication(s) for each term and for both terms together, the number of publications (Y axis) per year (X axis) and the total number of publications
until 2017.





In this paper, we aim to review potential biomarkers for frailty,
deﬁned as a clinical syndrome of accelerated aging and multimorbidity.
To this end, we focused our attention on a selection of markers found to
be secreted and measurable in body ﬂuids, and previously associated
with the “hallmarks of aging” pathways (Lopez-Otin et al., 2013) and
used or predicted as biomarkers in preclinical or clinical settings. We
did not aim to generate an exhaustive list, but rather focus on promising
candidates based on the consortium’s evaluation and expertise. For
more details see Fig. 2 and Tables 1–8 and for concentration ranges of
the selected biomarkers in body ﬂuids see Fig. 5 and Table S1. As the
frailty index is deﬁned as an accumulation of deﬁcits, we propose here
that the accumulation of biomarker changes would be a promising,
novel approach for identifying and monitoring frailty in both human
and animal cohorts. In this context, this review aims to be the ﬁrst step
towards a better understanding of whether biomarkers, used in this
way, might help to assess frailty on a molecular basis. We propose, as a
logical second step in this process, the experimental validation of the
markers in frail cohorts and animal models.
2.2. Approach
The knowledge of genes and pathways that are dysregulated in
aging and age-related diseases has dramatically increased in recent
years and has been made available in several databases (http://
genomics.senescence.info/genes including GenAge, AnAge,
LongevityMap, CellAge, DrugAge, Digital Aging Atlas). These databases
are a great source for identifying potential markers of frailty, a clinical
syndrome of accelerated aging and multimorbidity. Our search of these
databases resulted in a list of approximately 300 genes. Cross-referen-
cing this extensive list with “frailty” we realised that less than 10% of
the genes identiﬁed had been previously associated with frailty in the
literature. Therefore, and as represented in Fig. 2, we decided to
broaden our search terms to focus our search on proteins that are
known to be secreted and measurable in body ﬂuids and that: a) had
been previously used as markers in age-related diseases or b) had been
linked to either “hallmark of aging pathways”, such as (1) inﬂamma-
tion, (2) mitochondria and apoptosis, (3) calcium homeostasis, (4) ﬁ-
brosis, (5) NMJ and neurons, (6) cytoskeleton and hormones, or clearly
linked to aging and age-related diseases (see Table 1–7). An intensive
literature search was done and the most promising candidates were
scored using the considerable expertise of consortium members, as well
as looking at the broader or narrow relation of each gene with frailty,
age-related disorders, and age-related pathways. Scores were given for
further prioritisation (see Fig. 3–5 and Tables 1–8), with the highest
scores being attributed to genes that were associated with frailty and
with more than one hallmark of aging. Nevertheless, this scoring system
is not designed to translate the direct relation of the gene with frailty
but, instead, the amount of positive correlations and the broadness of its
implication in the multimorbidity syndrome associated with frailty.
Therefore, a high priority score means that there is a considerable
amount of evidence to support the hypothesis that the marker is not
equally expressed in frail versus non-frail individuals, even if the
overall changes in the marker levels are relatively small. It is important
to stress that, according to our scoring system, high priority markers do
not always correspond to markers associated with large fold changes.
Actually, one would expect generally smaller changes for individual
markers than reported in fully manifested diseases. Instead, we support
the notion that, even if small, the accumulation of changes in a set of
markers with a broad coverage of aging-associated pathways and dis-
eases, will better correlate with frailty than a single marker that pre-
sents large fold changes.
3. Results and discussion
The literature search resulted in the analysis of 44 biomarkers.
Based on our scoring system, which takes into account connection to
age-related pathways and dysfunction, as well as tissue distribution, we
propose a core panel of 19 high priority markers and an expanded panel
with 22 medium priority markers. In addition, three low priority
markers are described. Most markers are proteins or genes, but we also
included other emerging biomarker candidates such as miRNAs and
microparticles.
3.1. Inﬂammation
Overall changes in the immune system, impacting both adaptive
and innate immune responses, have emerged as one of the most re-
levant “hallmarks of aging” processes and immunological factors were
among the ﬁrst markers described for frailty (Fahey et al., 2000). The
concept of inﬂammaging, ﬁrst proposed by Franceschi and colleagues
in 2000 (Franceschi et al., 2000) and recently revised (Monti et al.,
2017), is based on the hypothesis that the aging process is related to a
systemic increase in pro-inﬂammatory mediators from various sources.
This increase is either directly related to sustained exposure to in-
fectious agents throughout life, or to age-related changes in gut mi-
crobiota, to metabolic dysfunction as seen in obesity or to secretion of
antigens generated as a consequence of cell death and subsequent ac-
cumulation of cell debris. These so called danger signals vary depending
on the tissue of origin and the cell death trigger, and include multiple
metabolites, such as extracellular ATP (adenosine triphosphate), urate
crystals, amyloids, ceramides, succinate, and the alarmin HMGB1. In
addition, inﬂammaging is a dynamic process that can be propagated
locally to neighbouring cells or systemically from organ to organ by
circulating factors and microvesicles (Monti et al., 2017). Overall, in-
ﬂammaging results in a chronic stimulation of immune cells that
translate into a low-grade and long-lasting inﬂammation which inﬂu-
ences both innate and adaptive immune responses.
In addition, aging results in marked changes in immune cell phe-
notypes and function. For example, a shift from lymphoid to myeloid
diﬀerentiation was described for B and T cell populations. Similarly,
monocytes, macrophages, dendritic cells, and neutrophils go through
signiﬁcant functional modiﬁcations, such as reduced phagocytic ac-
tivity and changes in pattern recognition receptors (i.e. Toll-like re-
ceptors (TLRs) and RAGE), which are crucial for the detection of danger
Fig. 2. Research strategy and approach. (1) The Initial step of this research was a database search for genes regulated in aging or age-related diseases. (2) Genes were
then limited to secreted factors, factors measurable in body ﬂuids and factors previously used as biomarkers.(3) Selected markers were assigned to “hallmark of
aging” pathways or other principles and (4) an extensive literature search was performed for each selected marker.
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signals. Moreover, immune cells change their surface marker expres-
sion, are less eﬃcient in the production of reactive oxygen species
(ROS), show compromised migration capacity, and favour the produc-
tion of pro-inﬂammatory over anti-inﬂammatory cytokines. Overall,
this phenotype called “immunosenescence” contributes to the accu-
mulation of cellular and molecular damage in aging tissues, potentiates
many age-related disorders (e.g. atherosclerosis, diabetes, and neuro-
degenerative diseases), and most importantly diminish eﬃcient re-
sponse to infections, cancer and other tissue injury.
Accumulation of senescent cells is an additional driver of age-re-
lated phenotypes in many tissues and organs (Baker et al., 2011). Se-
nescent cells are in growth arrest, but remain highly metabolically ac-
tive and gradually acquire a secretory phenotype called senescence-
associated secretory phenotype (SASP). SASP contains a variety of
factors, including inﬂammatory proteins, cytokines, chemokines,
growth factors, and matrix-remodelling enzymes which all negatively
inﬂuence tissue homeostasis and regeneration. SASP is also responsible
for spreading of senescence to neighbouring cells and tissues resulting
in progressive damage of tissues and organs. The most prominent
component of SASP is IL-6, whose elevated expression is associated
with genotoxic stress in multiple cell types such as epithelial cells, ﬁ-
broblasts, keratinocytes, and monocytes. In addition, serum IL-6 was
shown to be a predictor for disability and frailty (Soysal et al., 2016). As
previously mentioned, a big range of other bioactive molecules are also
secreted from senescent cells, including CRP (C reactive protein), IL-1α
(interleukin 1 alpha), IL-1β (interleukin 1 beta), TNF-α (tumour ne-
crosis factor alpha), IL-8 (interleukin 8), several chemokines, such as
CX3CL1, CXCL10 and CCL2 (C-C motif chemokine ligand 2), growth
factors, such as TGFβ and BDNF, and various proteases. Thus, it is not
surprising that molecules and SASP components involved in in-
ﬂammaging and immunosenescence are highly valuable biomarker
candidates for the chronic inﬂammatory phenotype seen in age-related
diseases and frailty. We have selected seven “inﬂammation” biomarker
candidates which are described below (see Tables 1,8, S1 and
Figs. 3–5).
CD14 antigen (also known as myeloid cell-speciﬁc leucine rich
glycoprotein), is a surface antigen preferentially expressed by mono-
cytes and macrophages. It binds exogenous danger signals such as
bacterial LPS (lipopolysaccharide) and triggers innate immune re-
sponses mediated by TLRs and NFκB (nuclear factor kappa B) signal-
ling. Homozygous CD14 null mice present immunologic changes, such
as impaired macrophage response to LPS or E. coli (Haziot et al., 1996)
as well as impaired cytokine production (Jeyaseelan et al., 2005), ac-
companied by a favourable musculoskeletal phenotype with increased
lean and body mass, reduced body fat, increased bone mineral density
and decreased susceptibility to bone fracture (Johnson et al., 2004).
In monocytes CD14 is, together with CD16, an important marker to
distinguish classical (CD14+/CD16-), intermediate (CD14+/CD16+),
and non-classical (CD14 dim/CD16+) subsets. Interestingly, in frail
individuals a shift of non-classical and classical towards intermediate
monocytes has been observed (Lu et al., 2016). Similar subset shifts
were found in coronary artery disease patients and shown to predict
adverse cardiovascular outcomes (Cappellari et al., 2017; Yoshida et al.,
2017). Moreover, in Alzheimer’s disease and rheumatoid arthritis pa-
tients, changes in total CD14 and increased intermediate monocytes
were observed (Le Page et al., 2017; Smiljanovic et al., 2018), in-
dicating an impaired innate immune response in these pathologies. The
intermediate monocyte phenotype has also been employed as an in-
tervention biomarker in coronary artery disease patients undergoing
lipid-lowering therapy (Yoshida et al., 2017). Despite these observa-
tions, CD14 expression is restricted to innate immune cells and the
criteria for distinguishing the diﬀerent monocyte subsets are not com-
pletely clear, which hinders its use as an overall frailty biomarker.
CX3CL1, (C-X3-C motif chemokine ligand 1, aka fractalkine), is a
unique chemokine, which exists as both membrane bound and soluble
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CX3CL1 acts as chemo-attractant for T-cells, NK (natural killer) cells,
and monocytes, while the membrane-bound form promotes adhesion of
neutrophils to endothelial cells and contributes to the selective re-
cruitment of monocytes to inﬂamed tissues (Jones et al., 2010; Kerfoot
et al., 2003). In addition, CX3CL1 plays a role in angiogenesis and
endothelial cell chemotaxis (Volin et al., 2010) as well as in diﬀerent
pathogenic conditions, including cancer, vasculitis, neuropathies, and
atherosclerosis. The CX3CL1 gene is widely expressed in tissues and
secreted into bio ﬂuids such as plasma, saliva, synovial liquid, and
cerebrospinal ﬂuid.
CX3CL1 has a high potential as biomarker for frailty and aging-as-
sociated diseases and indeed, changes in CX3CL1 signalling were re-
ported in frail elderly. Expression of CX3CL1 receptor (CX3CR1) in
monocytes positively correlates with dementia and is negatively asso-
ciated with anaemia and diabetes (Verschoor et al., 2014). Moreover,
CX3CL1 expression is enhanced by TNF-α and IFN-γ (Interferon-γ) and
in rheumatoid arthritis patients high levels are detected in synovial
ﬂuid which promotes the migration of monocytes, T-cells, and osteo-
clast precursors into joints (Ruth et al., 2001). Deletion of CX3CL1
signiﬁcantly improved rheumatoid arthritis in animals (Nanki et al.,
2017), and synovial and serum CX3CL1 were positively associated with
self-reported pain and physical disability in osteoarthritis (Huo et al.,
2015).
In brain disorders, CX3CL1 may have controversial functions.
Generally, CX3CL1 is highly abundant in brains of young, but decreased
in aged rodents. CX3CL1 signalling seems to increase amyloid pa-
thology, but contrarily soluble CX3CL1 may prevent taupathies (Merino
et al., 2016). Similarly, CX3CR1 knockout resulted in neuroprotection
in Parkinson’s disease, and multiple sclerosis disease models, but had
neurotoxic action in Alzheimer’s disease models (Lauro et al., 2015),
despite the fact that in human serum CX3CL1 was signiﬁcantly greater
in subjects with mild to moderate Alzheimer’s disease than with severe
disease (Kim et al., 2008b). In addition, there was a positive correlation
between mini-mental status examination score and plasma CX3CL1 in
the patients with Alzheimer’s disease (Rogers et al., 2011).
CX3CL1 levels were positively associated in a cohort of about 4000
patients with risk factors for several cardiovascular diseases and me-
tabolic traits, lower estimated glomerular ﬁltration rate, and higher
levels of inﬂammatory cytokines (Shah et al., 2015). Actually, increased
risk for death and/or myocardial infarction were observed in patients
with high CX3CL1 levels. Plasma CX3CL1 also increased in various
coronary artery disease populations (Damas et al., 2005) and here it
was shown to exert cytotoxic eﬀects on endothelium, as well as anti-
apoptotic and proliferative eﬀects on vascular cells aﬀecting athero-
sclerotic plaques (Apostolakis and Spandidos, 2013). Moreover, serum
CX3CL1 in patients with atherosclerotic carotid artery disease was
signiﬁcantly elevated when carotid stenosis was near occlusion (Stolla
et al., 2012). In adipose tissue, CX3CL1 is considered a novel in-
ﬂammatory adipokine that modulates monocyte adhesion to adipocytes
and is associated with obesity, insulin resistance, and type 2 diabetes
(Shah et al., 2011). In accordance, CX3CL1 together with secreted
Frizzled-related protein 4 (SFRP4) is associated with low-grade in-
ﬂammation in adipose tissue linking obesity to impaired insulin secre-
tion and glucose metabolism (Bergmann and Sypniewska, 2014). In-
creased CX3CL1 is also correlated with better prognosis in some type of
cancers, such as glioma, breast, and colon cancer (Andre et al., 2006;
Locatelli et al., 2010; Park et al., 2012). While CX3CR1 usually con-
tributes to tumour metastasis, CX3CL1 promotes aggregation of
CX3CR1 and attracts cytotoxic eﬀector T-cells or NK cells, decreasing
the invasiveness of the cancer. Importantly, beside its general potential
as inﬂammatory biomarker, CX3CL1 can be used to monitor pharma-
cologic interventions with anti-inﬂammatory agents shown to alter
CX3CL1 expression such as Etanercept, Rheumavax, Baicalin, Cyclo-
phosphamide, and corticosteroids (Benham et al., 2015; Ding et al.,
2016; Sato et al., 2011).
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complement activation. It is induced by various inﬂammatory cytokines
in peripheral blood leukocytes and myeloid dendritic cells, and acts as a
component of humoral innate immunity (Moalli et al., 2011; Musilova
et al., 2017). Pentraxin is also secreted by endothelial cells, vascular
smooth muscle cells, ﬁbroblasts, and adipocytes, promoting ﬁbrocyte
diﬀerentiation and playing a role in angiogenesis and tissue remodel-
ling.
Pentraxin has a strong potential as biomarker for frailty, since its
levels increase with age (Anuurad et al., 2011) and are also associated
with leukocyte telomere length (Pavanello et al., 2017). Moreover,
pentraxin expression has been reported to have prognostic value in
diﬀerent inﬂammatory conditions including sepsis (Liu et al., 2014a),
prostate inﬂammation (Stallone et al., 2014), amnion inﬂammation
(Musilova et al., 2017), appendicitis (Aygun et al., 2017), and hepatic
cirrhosis (Narciso-Schiavon et al., 2017). In a population-based study of
older men and women, pentraxin was associated with subclinical car-
diovascular disease and mortality (Jenny et al., 2009), as well as with
training-induced alteration of arterial stiﬀness in middle-aged and older
adults (Zempo-Miyaki et al., 2016). Obese individuals have a lower
pentraxin plasma concentration, whereas acute aerobic exercise
increases plasma pentraxin levels compared with normal-weight in-
dividuals (Slusher et al., 2017). Pentraxin might also have an ather-
oprotective role (Nakamura et al., 2015). Studies performed in osteo-
porosis patients reported altered pentraxin expression in osteoblasts
(Scimeca et al., 2017).
In the brain, pentraxin is a mediator of neurogenesis and involved in
cerebral ischemia. Astrocyte-derived pentraxin supports blood-brain
barrier integrity under the acute phase of stroke (Rodriguez-Grande
et al., 2015; Shindo et al., 2016). In addition, pentraxin may predict
tumour progression as low expression appears to facilitate tumour onset
and progression (Giacomini et al., 2018). Accordingly, pentraxin is
induced in the tumour stroma (cancer-associated macrophages and ﬁ-
broblasts) after chemotherapy in vitro (Chi et al., 2015).
However, inhibition of pentraxin in glioma cells was shown to im-
pair proliferation in vitro and in vivo (Tung et al., 2016) and suppression
of pentraxin in lung adenocarcinoma was found to block growth and
invasion (Hu et al., 2014) indicating a controversial role of pentraxin in
cancer.
sVCAM/sICAM (soluble vascular cell adhesion molecule 1/ soluble
Intercellular adhesion molecule 1) are immunoglobulin domain
Table 8
Biomarker prioritization. Scoring of selected biomarkers based on links to inﬂammation (Inﬂ), mitochondria (Mito), apoptosis (Apop), ﬁbrosis (Fibr), proliferation
(Prolif), stress response (Stre), cellular senescence (Senes), proteasome signaling (Prot) and tissue distribution (Tiss). Each score represents the sum of the “+”. “+
+”: strong evidence, “+”: ome evidence, “-“: no evidence. A total of 18 points could be reached and the following priorities were assigned: ≥12 (high: priority 1),
6–12 (medium: priority 2),< 6 (low: priority 3).
Pathway Marker INFL MITO APOP FIBR PROLIF STRESS SENES PROT TISS Score Priority
Inﬂammation IL-6 ++ ++ ++ ++ ++ – ++ – ++ 14 1
CXCL10 ++ + ++ + ++ – ++ + + 12 1
CX3CL1 ++ ++ ++ ++ ++ – + – + 12 1
Pentraxin ++ – – ++ ++ – – – ++ 8 2
sVCAM/sICAM ++ – – – + + ++ – ++ 8 2
Defensin ++ – ++ – – + – + ++ 8 2
CD14 ++ + – – – – – – + 4 3
Mitochondria
& Apoptosis
GDF15 ++ ++ ++ ++ – ++ + – ++ 13 1
FNDC5 ++ ++ ++ + – ++ + – ++ 12 1
Vimentin ++ ++ + + + + + + ++ 12 1
LDH + ++ + + + + + – ++ 10 2
APP ++ ++ + – + – + + + 9 2
Calcium
homeostasis
Regucalcin + ++ ++ ++ + + ++ – ++ 13 1
Calreticulin + + ++ + ++ ++ ++ – ++ 13 1
S100B + + + + + + + + ++ 10 2
Fibrosis AGT ++ ++ ++ + + + + – ++ 12 1
PLAU ++ ++ ++ + + – + ++ + 12 1
TGFβ + + – ++ + + ++ – ++ 10 2
PAI-1 – – ++ ++ + + ++ – ++ 10 2
TGM2 ++ – – ++ + – – – ++ 7 2
MMP7 + – – ++ – – – – ++ 5 3
THBS – – – ++ – – – – ++ 4 3
NMJ &
Neurons
Progranulin ++ ++ + + ++ + – ++ ++ 13 1
BDNF ++ + ++ – + ++ + ++ + 12 1
Agrin ++ + + ++ + – – + ++ 10 2
C3/C1q ++ + ++ – + – + – ++ 9 2
sRAGE ++ + + – + + – + – 7 2
HMGB1 ++ + + – – – ++ – + 7 2
ST2 ++ – – ++ ++ – – – + 7 2
Cytoskeleton
& hormones
FGF21 ++ ++ ++ ++ + ++ + – ++ 14 1
α-Klotho ++ + ++ ++ ++ – ++ – ++ 13 1
FGF23 ++ + ++ ++ ++ – ++ – ++ 13 1
Leptin ++ ++ ++ + ++ + + – + 12 1
Ghrelin + ++ ++ + ++ – – ++ + 11 2
IGF-1 ++ ++ – – + – ++ + ++ 10 2
GH + + + – ++ + – – ++ 8 2
Resistin ++ ++ ++ – + – – – + 8 2
Adiponectin ++ + ++ – + – – + + 8 2
Other
principles
miRNA panela ++ ++ ++ ++ ++ ++ ++ ++ ++ 18 1
AHCY ++ ++ + ++ + + + + ++ 13 1
KRT18 + ++ ++ ++ – ++ + – ++ 12 1
Microparticle panela ++ + ++ ++ – + + – ++ 11 2
Lactoferrin ++ ++ + + + + + + + 11 2
GpnmB ++ – + ++ + + + – ++ 10 2
a Panel needs further deﬁnition.
A.L. Cardoso et al. Ageing Research Reviews 47 (2018) 214–277
236
superfamily adhesion molecules expressed primarily on endothelial
cells and activated leukocytes, where they mediate leukocyte-en-
dothelium interaction and transendothelial migration during in-
ﬂammation. Actually, inﬂammatory mediators initially increase cell
surface expression of these molecules, to promote protease-dependent
shedding of the extracellular moieties in the form of soluble sVCAM and
sICAM fragments. While this initial process has an anti-inﬂammatory
action by inhibiting further leukocyte recruitment at the injury site,
release of both sVCAM/sICAM into plasma results in rather detrimental
eﬀects such as endothelial injury, vascular inﬂammation, athero-
sclerosis, hypertension, and systemic endothelial dysfunction
(Blankenberg et al., 2003; Tchalla et al., 2015). Thus not surprisingly,
sVCAM/sICAM levels are used as risk predictors for cardiovascular
events in healthy populations and various settings of disease, including
type 2 diabetes (Moradi et al., 2018; Mulvihill et al., 2002).
A direct link between sVCAM/sICAM and frailty and aging has been
reported. In frail elderly, elevated sVCAM-1 levels were associated with
more severe cerebral blood ﬂow dysregulation, mobility impairment
and falls. Moreover, sICAM levels were increased stepwise in non-frail,
pre-frail, and frail elderly people in a Taiwanese cohort, in a fashion
that was independent of IL-6 levels. Conversely, an inverse relationship
between plasma sVCAM/sICAM and the risk of cancer, another age-
related condition mechanistically linked to inﬂammation and angio-
genesis, has been observed (Tobias et al., 2017; Wang et al., 2015a).
Finally, release of sICAM from senescent cells via microvesicles was also
reported (Eﬀenberger et al., 2014), further supporting a major role of
sVCAM/sICAM in age and age-related diseases.
IL-6 (interleukin 6), one of the most prominent interleukins, is ex-
pressed in a variety of tissues including skeletal muscle, urinary
bladder, gall bladder, appendix, oesophagus, bone marrow, lung,
adrenal, prostate, and adipose tissues. It is primarily produced at in-
ﬂammation sites, secreted into serum and induces a transcriptional
inﬂammatory response through IL-6RA (IL-6 receptor, alpha). Roles of
IL-6 have been conﬁrmed in numerous pathophysiological conditions
such as inﬂammation (Sindhu et al., 2015), mitochondrial myopathy
(Rue et al., 2014), insulin resistance, cell proliferation (Chen et al.,
2018), apoptosis, and cellular senescence (Zhuang et al., 2017).
Moreover, IL-6 serum levels were also positively correlated with
aging (Carmeli et al., 2012; Tung et al., 2015) and many age-related
diseases, including cardiovascular (Athilingam et al., 2013), neurolo-
gical (Kim et al., 2017e; Kwan et al., 2013), musculoskeletal diseases,
and cancer (Athilingam et al., 2013). Signiﬁcantly higher levels of IL-6
in serum have been reported in almost every pathophysiological con-
dition if patients are compared to control groups. In accordance, phy-
sical training and nutritional support, two of the best validated anti-
aging factors, decrease or prevent increase in IL-6 levels in humans
(Haider et al., 2017).
CXCL10 (C-X-C motif chemokine 10) is a IFNγ- inducible chemokine
of the CXC subfamily and ligand for the receptor CXCR3, which is
mainly expressed by activated T-lymphocytes (Luster et al., 1985), but
also in other cell types such as ﬁbroblasts. Binding of CXCL10 to CXCR3
results in T-cell migration, but also in stimulation of monocytes and NK
cells, as well as modulation of adhesion molecule expression and in-
duction of apoptosis (Singh et al., 2010; Sui et al., 2006). CXCL10 is
currently considered to be one of the most useful biomarkers for a range
of infectious and inﬂammatory conditions (Ko et al., 2015; Otterdal
et al., 2016; Zhang et al., 2014a), but was also shown to increase in
human serum with age (Antonelli et al., 2006; Bonfante et al., 2017;
Shurin et al., 2007). CXCL10 is elevated in the hippocampus of senes-
cence-accelerated mice (Grinan-Ferre et al., 2016), as well as in the
aorta during normal aging in mice (Trott et al., 2017). Thus, increased
CXCL10 secretion may contribute to abnormal immune responses
which are observed in the elderly.
Recently, CXCL10 was identiﬁed as a major component of SASP in
human foetal lung ﬁbroblasts. Since CXCL10 can stimulate its own
transcription via CXCR3 and NFκB signalling, it has a positive feedback
on SASP and extensively promotes inﬂammation in surrounding tissues
(Perrott et al., 2017), as well as tumour cell growth, motility, and
metastasis (Wightman et al., 2015). The usefulness of CXCL10 as a se-
creted biomarker for aging and frailty-related conditions is further
supported by the fact that its increase with age is counteracted by nu-
merous interventions targeting aging, including caloric restriction
(Trott et al., 2017), resveratrol (Palomera-Avalos et al., 2018), met-
formin (Bakhashab et al., 2016) and general suppression of the SASP by
Fig. 3. Biomarker stratiﬁcation according to pathway and priority. Following extensive literature search, we propose a core panel of 19 frailty biomarkers (priority 1,
inner circle), as well as an expanded panel of 22 biomarkers (priority 2, middle circle). Markers that were not found to correlate signiﬁcantly with frailty were
considered priority 3 biomarkers (outer circle).
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the ﬂavone apigenin (Perrott et al., 2017).
Defensins are a large family of antimicrobial and cytotoxic peptides
involved in host defence and in immunomodulation (Holly et al., 2017).
They are small (18–45 residues), highly conserved cationic and am-
phipathic peptides that are distinguished by structure and conserved
cysteine motifs. The defensin α family is divided into a) enteric, which
are expressed in alimentary track, particularly in Paneth cells and
epithelial cells, and b) myeloid, mostly expressed in peripheral blood
cells, in particular neutrophils. Myeloid defensin α is the most pro-
mising biomarker for the accurate diagnosis of human periprosthetic
joint infection in synovial ﬂuid (Yuan et al., 2017), even though the
gene is not active in laboratory mice. The defensin β family members
are mostly expressed in endothelial cells of the skin and genitourinary,
gastrointestinal, and respiratory tracts. Serum levels of defensin β have
been explored as potential biomarkers for skin inﬂammation to monitor
psoriasis treatment response and disease activity (Jin et al., 2017).
From these seven potential inﬂammatory biomarkers for frailty we
identiﬁed three high priority (IL-6, CXCL10, CX3CL1), three medium
priority (pentraxin, sVCAM/sICAM, defensin) and one low priority
candidate (CD14).
IL-6 was by far the most convincing candidate with broad functional
coverage and potential as a diagnostic, prognostic, and therapeutic
biomarker, followed by CXCL10 and CX3CL1 which display similar
potential and all three are clear candidates for the core panel. The three
medium priority markers were of similar value and overall had more
limited or indirect functions than high priority markers. In particular,
for defensins which are highly important for innate immune responses,
more data are needed to deﬁne the speciﬁc isoforms that correlate to
frailty. CD14 was assigned low priority because it is an indirect marker
with rather narrow coverage compared to other candidates and its role
is limited to the inﬂammatory response (see Tables 1,8).
3.2. Mitochondria and apoptosis
Mitochondria play a central role in the production of ATP, and in
the decline of basal metabolic rate and physical performance, and in
energy-requiring tasks, which are characteristic of several age-related
disorders. An age-dependent impairment of mitochondrial function
includes decreased electron transfer rates, increased permeability to H
+ of the inner membrane, and impaired ATP synthesis. Both mi-
tochondrial complex activities and enzyme activities of the tri-
carboxylic acid activities are reduced (Papa and Skulachev, 1997;
Fig. 4. Tissue distribution of priority 1 frailty biomarkers. Biomarker tissue distribution is shown for the core panel of markers (adapted from Petryszak, PMID
26481351). Markers are shown in bold in the organ with highest marker expression.
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Pollack and Leeuwenburgh, 2001). Moreover, mitochondrial DNA
mutations accumulate in aging. In fact, the PolG mouse, a model mi-
micking increased mitochondrial mutations, displays a progeroid,
multi-morbid, and frail phenotype (Li et al., 2017c; Safdar et al., 2011;
Szczepanowska and Trifunovic, 2017).
Apoptosis, a process closely linked to mitochondrial dysfunction
(Wang and Youle, 2009), is also elevated in the aging process (Pollack
and Leeuwenburgh, 2001). Apoptotic proteins target mitochondria in
various ways inducing membrane pores, caspase-activity, and mi-
tochondrial swelling or changes in mitochondrial membrane perme-
ability, thus ceasing mitochondrial respiration and leading to cell death.
Similarly, autophagy, the most important process for mitochondrial
turnover, also shows age-associated dysregulation (Carroll and Martin,
2013; Lee et al., 2012a). Recently, Patterson and colleagues revealed a
mechanistic link between human aging and the risk of amyloidosis
which may result from a dramatic slowing of amyloid-β turnover,
which promotes protein misfolding and deposition (Patterson et al.,
2015).
All cells, but in particular brain and muscle cells are particularly
susceptible to mitochondrial dysfunction associated with oxidative
damage, as large amounts of ATP are required to maintain neuronal
processes and contractile function. As a consequence, a high O2 and
glucose consumption occurs, leading to a continuous production of ROS
during the oxidative phosphorylation process. Aged cells show signs of
increased oxidative stress, mitochondrial dysfunction, and accumula-
tion of misfolded proteins, which are exacerbated in aged-related
neurological and other disorders (Sas et al., 2018). We have selected
ﬁve “mitochondrial and apoptosis” biomarker candidates which are
described below (see Tables 2,8, S1 and Figs. 3–5).
GDF15 (growth diﬀerentiation factor 15), also called myomitokine,
Fig. 5. Concentration ranges for frailty biomarkers in serum/plasma. The graph shows the expected concentration range of the proposed frailty biomarkers in human
plasma or serum, according to the literature.
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is a pleiotropic cytokine ubiquitously secreted after stress response and
injury which seems to activate GFRAL (GDNF family alpha like), a re-
ceptor linked to stress and apoptosis. In addition, GDF15 is extensively
studied as biomarker for various diseases, including chronic in-
ﬂammation, cancer, musculoskeletal, cardiovascular, kidney, liver, and
neurological diseases (Corre et al., 2013).
In various studies, elevated GDF15 predicted mortality and disease
progression. There are also studies directly assessing aging and age-
related disorders showing that GDF15 can be used as a biomarker for
mitochondrial dysfunction (Fujita et al., 2016b), for cognitive aging
and dementia (Jiang et al., 2015a), for vascular pathologies (Eggers
et al., 2012) and as independent predictor of mortality risk in the
Rancho Bernardo community-dwelling older adult study (Daniels et al.,
2011) and other causes of mortality (Wiklund et al., 2010). In addition,
it predicts physical decline, diabetes, and insulin resistance, correlates
negatively with muscle mass and many other age-related morbidities.
GDF15 has been successfully used as an intervention biomarker, for
example, for the use of metformin in people with dysglycemia (Gerstein
et al., 2017) and for pyruvate therapy in mitochondrial diseases (Fujita
et al., 2015).
FNDC5 (ﬁbronectin type III domain containing 5), is a widely ex-
pressed transmembrane-protein which undergoes proteolytic proces-
sing to produce the secreted myokine irisin. It was only recently iden-
tiﬁed (Bostrom et al., 2012), shown to positively regulate brown fat
diﬀerentiation, and proposed as a potential therapeutic target for me-
tabolic and other disease. Since its identiﬁcation, irisin has been ex-
tensively studied, originating in more than 500 publications. Irisin
promotes mitochondrial biogenesis, preserves mitochondrial function
in hypoxic conditions (Bostrom et al., 2012; Wang et al., 2017c; Xie
et al., 2015; Zhang et al., 2014b), protects from apoptosis (Liu et al.,
2017e; Natalicchio et al., 2017; Shao et al., 2017; Sugiyama et al.,
2017), and has anti-inﬂammatory activity (Baran et al., 2017; Matsuo
et al., 2015; Mazur-Bialy, 2017; Mazur-Bialy et al., 2017; Peng et al.,
2017; Usluogullari et al., 2017).
Studies in aging showed that low irisin levels could predict sarco-
penia (Chang et al., 2017a; Lee et al., 2015b), atherosclerosis (Icli et al.,
2016; Lee et al., 2015b), and were associated with osteoporotic frac-
tures (Anastasilakis et al., 2014). Irisin also correlated positively with
global cognition and contributes to the neuroprotective eﬀect of ex-
ercise (Kuster et al., 2017; Li et al., 2017a; Wrann et al., 2013). Prog-
nostic and therapeutic eﬀects were shown in metabolic and cardio-
vascular conditions (for review see (Perakakis et al., 2017). For
example, irisin seems to predict mortality in acute heart failure (Shen
et al., 2017) and increased irisin improved obesity, glucose home-
ostasis, and ischemia-induced heart injury (Assyov et al., 2016; Chen
et al., 2015a; Du et al., 2016; Jang et al., 2017; Tanisawa et al., 2014;
Wang et al., 2017c). Similarly, irisin was associated with liver, kidney,
and eye diseases (Hu et al., 2016b; Polyzos et al., 2014; Wen et al.,
2013). Interestingly, serum irisin levels are elevated in healthy cen-
tenarians and reduced in young patients with myocardial infarction
(Aydin et al., 2014; Emanuele et al., 2014). In addition, plasma irisin
levels were shown to be increased by exercise (Fox et al., 2018; Hew-
Butler et al., 2015; Jedrychowski et al., 2015), following healthy diet
(Crujeiras et al., 2014; Ko et al., 2016), by antihypertensive drugs (Celik
et al., 2015), by a combination of isoprost and sildenaﬁl used to reduce
myocardial ischemia (Aydin et al., 2017), and with metformin treat-
ment (Li et al., 2015b). Nevertheless, some of the irisin ﬁndings are
controversial and need further evaluation.
Vimentin (VIM) is a ubiquitously expressed type III intermediate
ﬁlament protein which is cleaved by caspases. Vimentin cleavage dis-
rupts the cytoplasmic network of intermediate ﬁlaments and produces
pro-apoptotic fragments (Byun et al., 2001). If vimentin is released
from apoptotic cells it can be mutated and citrullinated, subsequently
producing autoantigens and inducing antibodies against the mutated
and citrullinated form (MCV). These autoantibodies are used as bio-
markers in rheumatoid arthritis patients and maybe also useful for
idiopathic pulmonary ﬁbrosis patients (Reyes-Castillo et al., 2015; Zhu
and Feng, 2013). Vimentin is also known as an epithelial to mesench-
ymal transition biomarker (Dong et al., 2017a) and, thus, used as a
diagnostic, prognostic, and therapeutic marker in ﬁbrotic diseases
(Schiﬀers et al., 2000; Wolcott et al., 2017; Wu et al., 2017c). For ex-
ample, vimentin was shown to be increased in the urine of chronic
kidney disease patients (Cao et al., 2015). In accordance with its role in
ﬁbrosis, vimentin expression is also regulated by TGFβ and pro-in-
ﬂammatory cytokines.
We would like to note that in addition to vimentin there are several
caspase-cleaved fragments described as disease biomarkers, such as, for
example, Keratin 18 in liver disease (Lee et al., 2017), myosin-light
chain (Petrache et al., 2003) or myosin-heavy chain in cardiac diseases
(Communal et al., 2002). These fragments also have potential as frailty
biomarker candidates and Keratin18 is included in Section 3.4 on ﬁ-
brosis.
APP (Amyloid precursor protein beta) is a precursor membrane
protein, which matures in the Golgi complex, and is later cleaved and
secreted in the extracellular space as soluble APP peptides.
In Alzheimer’s disease and cerebroarterial amyloidosis patients,
amyloid plaques are formed by insoluble peptides generated from al-
ternative cleavage (e.g. Aβ40 and Aβ42) and various treatments tar-
geting these plaques have been explored in patients (e.g. Lanabecestat,
(Sakamoto et al., 2017)), or APP transgenic mice (NB-360, (Neumann
et al., 2015), Liratuglide, (McClean et al., 2015)). Secretion of APP
peptides and plaque formation depend on autophagy (Cai et al., 2015;
Nilsson et al., 2013) and APP turnover was shown to be signiﬁcantly
slowed with increased age (Patterson et al., 2015).
Similar accumulation of APP peptides has also been described in
sporadic inclusion body myositis, the most common acquired muscle
disease in patients over 50 years (Lunemann et al., 2007), as well as in
metabolic and cardiovascular diseases, indicating a role of APP peptides
outside the central nervous system (CNS). APPs can also be measured as
biomarkers in circulation and were shown to predict the outcome in
diﬀerent diseases, including ischemic stroke (Liu et al., 2015) and heart
failure (Bayes-Genis et al., 2017).
LDH (lactate dehydrogenase), catalyses the simultaneous con-
version of pyruvate to lactate and NADH (nicotinamide adenine dinu-
cleotide) to NAD+and is needed in almost every single cell. LDH
isoforms are expressed in a tissue-speciﬁc manner (e.g. LDHA in skeletal
muscle, LDHB in the heart) and secreted during tissue damage and
injury. Thus, elevated LDH levels reﬂect tissue breakdown and are used
as a common marker for tissue injury and various age-related diseases
including heart failure, cancer, neurodegeneration, lung, or liver dis-
ease. For example, plasma LDH is elevated in acute myocardial in-
farction (Wei et al., 2014) and amyloidosis and was shown to predict
mortality in acute aortic syndrome and prognosis in patient with solid
tumours (Agrawal et al., 2016; Petrelli et al., 2015; Yu et al., 2017c). In
cancer LDH levels are associated with systemic inﬂammatory responses
and predict survival and outcome in patients treated with anti-PD-1
therapy (Diem et al., 2016). Furthermore, LDH inhibitors were shown
to reverse inﬂammation-induced eﬀects in cancer cells indicating other
possible roles.
In summary, from the ﬁve markers in the mitochondria and
apoptosis category, the proﬁle of GDF15, FNDC5 and vimentin – in
predicting diagnostic, prognostic, and therapeutic potential - seems
optimal enough to be included in the core biomarker panel for (see
Table 8). Increased levels of GDF15 and vimentin, but reduced levels of
FNDC5 would be expected in multi-morbid, frail people. Whereas
FNDC5 and GDF15 represent biomarkers of mitochondrial dysfunction,
vimentin, vimentin fragments, or MCV antibodies are more apoptotic
and ﬁbrotic (see also ﬁbrosis) biomarkers of frailty. LDH reached
medium priority as marker for the expanded panel being useful to
monitor general tissue homeostasis and damage. In addition, the source
of tissue damage could be further determined by measuring the levels of
various isoforms. Similarly, APP is assigned to the expanded panel,
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mainly due to its more focused function and tissue distribution.
3.3. Calcium homeostasis
Calcium plays an important role in many physiologic and patho-
physiologic processes both extracellularly and intracellularly.
Intracellular calcium signalling, such as second messengers for GPCR
(G-protein coupled receptors) and other receptors, is essential in any
living cell as it allows eﬃcient muscle contraction, hormone and neu-
rotransmitter release, cell survival, and apoptosis. Dysregulation of
calcium can include availability, intracellular translocation, and utili-
sation. Calcium levels have quite narrow limits and small changes may
cause tremendous dysfunction. Calcium is absorbed in the gut, excreted
by the kidney and its levels are mainly regulated by the parathyroid
hormone. Calcium is mainly stored in muscles, heart, and bone. Within
the cell, the endoplasmic reticulum (ER) and mitochondria are the main
storage and under homeostatic conditions relatively low concentrations
of calcium occur in the cytoplasm. Cell contractility, cell viability and
the activity of a large number of enzymes are calcium dependent. A big
fraction of calcium is protein bound and calcium binding proteins have
diﬀerent cellular and tissue distribution and speciﬁc functions. So, it is
not surprising that calcium homeostasis is dysregulated in many organ
dysfunctions and diseases (for recent review see (Giorgi et al., 2018)).
Measuring calcium levels is not an ideal method for detecting changes
in calcium homeostasis due to the many inﬂuencing parameters and
dependency of function on local availability. However, changes in
calcium signalling and/or binding proteins have been proven to be ef-
fective markers of cellular and tissue dysfunction induced by disturbed
calcium homeostasis. In the following section three “calcium home-
ostasis” biomarker candidates are described (see Tables 3,8, S1 and
Figs. 3–5).
S100B (S100 calcium binding protein B) is one of 24 members of
the S100 calcium-binding protein family and exerts both intracellular
and extracellular functions in calcium signalling. As a consequence,
S100B is involved in the regulation of a number of cellular processes
such as cell-cycle progression and diﬀerentiation. (for review see
(Donato et al., 2013b). This protein is ubiquitously expressed but en-
riched in brain and adipose tissue. S100B protein is involved in tissue
development, repair and regeneration and many of its binding partners
modulate pathways dysregulated in chronic and age-related diseases
(e.g. p53, NFκB).
Transgenic animals conﬁrm a role of S100B in age-related diseases
as S100B overexpressing animals display premature aging, whereas
diﬀerent S100B-deﬁcient mice were generated with overall normal
development and no severe impairment of motor function.
Interestingly, one mouse strain showed allodynia (Bluhm et al., 2015).
In addition, serum S100B is positively associated with better cognitive
performance in healthy older adults (Lam et al., 2013). In inﬂammatory
disorders, S100B plays a pathophysiologic role as shown for brain
(Villarreal et al., 2014), obesity-related inﬂammation, (Buckman et al.,
2014) and in the gut (Cirillo et al., 2011). For example, systemic in-
ﬂammation is associated with high S100B in acute ischaemic stroke
(Beer et al., 2010). In cancer, S100B-induced suppression of p53 con-
tributes to cancer progression (Lin et al., 2010), whereas S100B protein
levels are elevated in central nervous system disorders, Down Syndrome
(Netto et al., 2005) and Alzheimer’s disease (Ferguson et al., 2017).
S100B blood levels have been suggested as biomarker to predict the
progress or the prognosis of subarachnoid haemorrhage (Chong, 2016).
S100B can also be detected in exosomes from melanoma patients and
their quantiﬁcation presents diagnostic and prognostic utility (Alegre
et al., 2016). Moreover, pharmacologic inhibition of S100B (e.g. with
the anti-microbial agent pentamidine) is being considered as a ther-
apeutic option in brain injury (Cirillo et al., 2015), cerebral ischemia
and Alzheimer’s disease (Mori et al., 2010), acute colitis (Esposito et al.,
2012), and malignant melanoma (Smith et al., 2010) (see Tables 3,8, S1
and Figs. 3–5).
Regucalcin (RGN), also known as senescence-marker protein 30
(SMP30), is a gluconolactonase and one of the ﬁrst described bio-
markers shown to decrease with aging. It is widely studied as a bio-
marker or diagnostic tool (Kim et al., 2012; Vaz et al., 2015;
Yamaguchi, 2014c; Zubiri et al., 2015). It has been shown to play a
multifunctional role in many cell types, mainly as intracellular calcium
signalling protein induced by oxidative stress that acts through mem-
brane pumps located on the plasma membrane, ER, sarcoplasmic re-
ticulum and mitochondria. For example, regucalcin increases Ca2+-
ATPase activity in heart, brain, and liver mitochondria (Akhter et al.,
2006; Takahashi and Yamaguchi, 2000; Yamaguchi et al., 2008), but
inhibits microsomal Ca2+-ATPase activity in the brain and other tis-
sues (Tobisawa et al., 2003). Consistent with its eﬀects on calcium
homeostasis regucalcin was shown to regulate the synthesis of DNA
(Deoxyribonucleic acid), RNA, and proteins, chronic inﬂammatory
processes, cell proliferation and cellular senescence (Fujisawa et al.,
2011; Yamaguchi, 2013a, b). Overall, regucalcin seems to be a potent
protective molecule against oxidative stress and chronic inﬂammation
in a broad range of tissues.
Studies in transgenic animals further validated the role of regucalcin
in aging and frailty. SMP30 knockouts have a shortened life-span, and
elevated pro-inﬂammatory marker levels, and further increase
Parkinson’s disease and other age-related pathologies (Kim et al., 2012;
Maruyama et al., 2004). Actually, regucalcin plays a pivotal role in
vitamin C biosynthesis, and vitamin C deﬁciency induces shortened
lifespan and accelerated aging in SMP30 knockouts (Ishigami, 2010). In
contrast, overexpression of SMP30 protects against age-related dis-
orders (Kim et al., 2012; Vaz et al., 2015), a number of stress-induced
insults, as well as apoptosis and cell growth (Akhter et al., 2006; Correia
et al., 2017; Maruyama et al., 2004). Regucalcin is signiﬁcantly de-
creased with increasing age in various tissues such as the heart, brain,
and prostate, and these reduced levels induce cellular senescence,
frailty, ﬁbrotic and other injuries in various organs including the liver,
heart, kidney, and brain. For example, regucalcin is reduced in cirrhotic
livers, particularly in ﬁbrotic tissue, in various kidney diseases and also
in heart failure where reduced regucalcin may play a key pathophy-
siologic role through the impaired activation of SOD (superoxide dis-
mutase), an enzyme that under healthy conditions prevents cell death
and apoptosis in the heart. Reduced regucalcin levels were also shown
in various cancers (e.g. liver and pancreas) in association with worse
survival (Tsurusaki and Yamaguchi, 2004; Yamaguchi and Murata,
2015; Yamaguchi et al., 2016).
As mentioned, regucalcin or serum autoantibodies against reg-
ucalcin are used as biomarker in various conditions, including many
age-related diseases (Bystrom et al., 2017; Yamaguchi, 2014a,b). Be-
sides being a diagnostic tool, regucalcin can also be used as prognostic
and therapeutic marker. For example, in liver cirrhosis intervention
with glutathione inosine increased regucalcin and in parallel sig-
niﬁcantly reduced ﬁbrosis severity (Liu et al., 2014c). In addition, in-
tervention with EUK4010, a natural compound which protects against
Aβ42-induced loss of neuronal cell viability, and intervention with the
antihypertensive drug valsartan in settings of doxorubicin-induced
cardiotoxicity (Park et al., 2016) similarly restored regucalcin. Inter-
estingly, elevated regucalcin levels observed in Smad3-/- mice were
shown to protect against carbon tetrachloride-induced liver cirrhosis
and improve glucose utilisation, lipid production, and insulin resistance
in liver cells. In addition, the potential of regucalcin-based anticancer
gene therapy is currently under investigation based on work showing
reduced regucalcin levels in human tumours including kidney, lung,
brain, breast, and prostate cancers.
Calreticulin (CALR) is a multifunctional protein initially identiﬁed
as a Ca2+-storage protein in the ER. However, calreticulin is also ex-
pressed in mitochondria, at the surface of pre-apoptotic cells and in the
ER, where it binds to misfolded proteins to prevent their export.
Calreticulin has several functions in apoptosis and in the immune re-
sponse. For example, calreticulin inhibit LPS-induced inﬂammatory
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osteoclastogenesis in the mouse calvarian bone (Fischer et al., 2017)
and its presence at the surface of pre-apoptotic cells provides a signal
recognised by antigen-presenting cells to initiate phagocytosis. Inter-
estingly, calreticulin also interacts with APP at the γ-secretase cleavage
site suggesting a role in neurodegenerative diseases (Stemmer et al.,
2013).
Age-related levels of anti-Calreticulin antibodies were determined
in three groups of cynomolgus monkeys and statistically signiﬁcant
diﬀerences were noted among the aged group. Calreticulin is increased
in diﬀerent ﬁbrotic, chronic stress-induced or age-related diseases. For
example, chronic stress activates calreticulin and mediates pathologic
mechanisms in social defeat mice (Tomas-Roig et al., 2016). Circulating
calreticulin is increased in myeloﬁbrosis patients and highly correlates
with symptoms (e.g. bone marrow ﬁbrosis) and aggressiveness of the
disease (Sollazzo et al., 2016). Moreover, calreticulin is upregulated in
various cancers showing both prognostic and therapeutic use. Inter-
estingly, calreticulin mutations were observed in Philadelphia-negative
myeloproliferative neoplasm and these patients displayed a lower risk
of splenomegaly and thrombosis and were favourably aﬀected in
overall survival. Increased levels are also observed in various in-
ﬂammatory diseases, such as systemic lupus erythematosus, juvenile
arthritis, bronchiectasis and rheumatoid arthritis where they are used
as both a diagnostic and prognostic marker. In the heart, calreticulin is
upregulated by cardiomyopathy inducers as well as angiotensin II
(ATII) which causes mitochondrial injury and subsequently myocardial
hypertrophy (Shan et al., 2014; Zhang et al., 2013); in addition, over-
expression of calreticulin directly induces cardiac dysfunction. In the
kidney, calreticulin is critically involved in the molecular mechanisms
that drive renal ﬁbrosis progression and inhibition of calreticulin might
be a therapeutic target for reduction of ﬁbrosis and chronic kidney
disease development (Bibi et al., 2011; Prakoura et al., 2013).
However, in the brain, calreticulin was described as neuroprotective
factor and is downregulated in Alzheimer’s disease cells and in the
amyotrophic lateral sclerosis model SOD1(G93 A). In the latter, back-
ground knockout of calreticulin further increased onset and degree of
muscle weakness and denervation compared to control SOD1(G93 A)
(Bernard-Marissal et al., 2015). In accordance with this, calreticulin is
down-regulated in cortical neurons of patients with Alzheimer’s disease
and is considered a potential biomarker for the diagnosis of Alzheimer’s
disease (Lin et al., 2014). Caloric restriction helped to maintain calre-
ticulin expression in brains of 15-month old mice restricted for one year
(Schafer et al., 2015).
Presently, calreticulin and auto-antibodies against calreticulin serve
as biomarkers in various chronic and ﬁbrotic conditions, including age-
related diseases (Caira et al., 2017; Clarke et al., 2017; Ding et al., 2014;
Guo et al., 2002; Lee et al., 2013; Ohadi et al., 2012). Besides re-
presenting a diagnostic and prognostic tool calreticulin may also be
used as a direct therapeutic target or eﬃcacy marker to monitor ther-
apeutic interventions. For example, ZnCl2 has the potential to enhance
the therapeutic eﬀects of anti-neoplastic agents partly by promoting
calreticulin expression in cancer cells which activates dendritic cells
and anti-tumour immune response (Cirone et al., 2013). Similarly, an-
thracyclines induce pre-apoptotic translocation of calreticulin to the
cell surface to promote anti-cancer immune response and recombinant
calreticulin increased cure rates of photodynamic therapy for squamous
cell carcinoma in immunocompetent mice (Korbelik et al., 2015). Fi-
nally, treatment with the anti-viral bee toxin mellitin restored TNFα-
induced calreticulin expression in smooth muscle cells (Cho et al.,
2013).
Overall, the data available show that increased calreticulin levels
were observed in most systemic pathologic conditions. However, in
neurodegeneration calreticulin is reduced and its restoration induces
neuroprotection.
In summary, from the three selected candidates involved in cal-
cium homeostasis, both regucalcin and calreticulin reached high
priority and are assigned to the core panel, whereas S100B will be
included in the expanded panel.
3.4. Fibrosis
Fibrosis is the formation of ﬁbrous tissue which can be part of the
normal wound healing process after injury, later being replaced by
newly formed healthy tissue. However, ﬁbrotic tissue can also perma-
nently replace functional tissue, for example, as a result of aging, when
the healing process becomes sub-optimal and ﬁbrotic tissue builds up in
organs such as the heart, lungs, kidneys, or liver and hampers normal
tissue function. Improper tissue repair leads to hyperproliferation and
enhanced inﬂammation due to the presence of a variety of in-
ﬂammatory cells (neutrophils and macrophages). In addition, un-
controlled protease activity interferes with normal repair mechanisms
and this may lead to increases in ﬁbrotic tissue as some ﬁbroblasts
become senescent and may secrete SASP. In some cases, there is a re-
duction of angiogenesis accompanied by stem cell recruitment leading
to aberrant extracellular matrix (ECM) remodelling (Eming et al.,
2014). Cytokines, such as IL-13 (interleukin 13), IL-21 (interleukin 21),
TGFβ, BMPs (bone morphogenic proteins), chemokines such as MCP-1
(monocyte chemoattractant protein 1) and MIP-1β (macrophage in-
ﬂammatory protein-1β) have been implicated in ﬁbrosis. In addition,
angiogenic factors (e.g. VEGF (vascular endothelial growth factor)),
growth factors (e.g. PDGF (platelet derived growth factor)), and acute
phase proteins, caspases and proteases, and components of the RAS
(renin angiotensin aldosterone) system have been identiﬁed as im-
portant regulators of ﬁbrosis and are being investigated as potential
targets of anti-ﬁbrotic drugs (Wynn, 2008). Fibrosis is seen in multiple
organs, in particular the heart, lung, kidney, and liver (Zeisberg and
Kalluri, 2013).
As mentioned above, the TGFβ pathway, which is activated by a
variety of molecules such as the three TGFβ isoforms (TGFβ1, TGFβ2,
and TGFβ3), BMPs, GDFs (growth and diﬀerentiation factors), AMH
(anti-Müllerian hormone), activins, and nodal, plays a major role in
ﬁbrosis. These molecules regulate tissue regeneration, cell diﬀerentia-
tion, embryonic development, and immune system diﬀerentiation and
respond via TGFβ, activin and BMP receptors and, mainly canonical
SMAD signalling. The TGFβ pathway is important for many processes
starting early after embryonic development, but also later in life and is
therefore an interesting source for biomarkers of aging and particularly
frailty. So not surprisingly, several TGFβ pathway molecules were
identiﬁed as potential biomarkers for aging or frailty and our review
includes seven “ﬁbrosis” biomarker candidates discussed in this section
(see Tables 4,8, S1 and Figs. 3–5).
TGF-β (Transforming growth factor beta) is a pleiotropic cytokine
belonging to the transforming growth factor superfamily and consists of
three diﬀerent isoforms (TGFβ1, TGFβ2, and TGFβ3). All TGFβ iso-
forms are produced and secreted as latent proteins, and locally acti-
vated by various mechanisms to perform cellular functions, including
the control of cell growth, cell proliferation, cell diﬀerentiation, and
apoptosis. TGFβ1 is the main endocrine isoform (Zhao et al., 2017a),
whereas TGFβ2 and TGFβ3 have mainly para- and autocrine function
(Rodon et al., 2014; Van Themsche et al., 2010).
Higher concentrations of TGFβ are found in the blood and cere-
brospinal ﬂuid of Alzheimer’s disease patients compared control sub-
jects (Swardfager et al., 2010), suggesting a possible role in the neu-
rodegenerative cascade leading to Alzheimer’s disease. Associations of
TGFβs with various diseases have been newly discovered or elucidated
in much more detail than before, including atherosclerosis, acute and
chronic liver and kidney disease, autoimmunity, osteoarthritis and
neurodegenerative diseases and many of these disease are associated
with aging and frailty (Krieglstein et al., 2012).
PAI-1 (Plasminogen activator inhibitor 1, also known as Serpine
E1), is the principal inhibitor of tissue (PLAT) and PLAU, and acts as an
inhibitor of ﬁbrinolysis. PAI-1 is induced by the TGFβ pathway and is a
measurable SASP component (Eren et al., 2014; Ghosh et al., 2016).
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Defects in this gene cause PAI-1 deﬁciency, and high PAI-1 con-
centrations are associated with thrombophilia. Alternatively spliced
transcript variants have been found for this gene with diﬀerent func-
tions. Elevated PAI-1 levels are, in fact, a signiﬁcant causative factor
and circulating biomarker in the pathophysiology of many age-related
diseases, including diabetes, vascular thrombosis, metabolic syndrome,
septic coagulopathy, atherosclerosis, restenosis, and myocardial in-
farction, particularly in the context of increased tissue TGFβ1 levels.
PAI-1 is also shown to be involved in many aging-associated disorders
and considered as a direct therapeutic target (Edelmann et al., 2015;
Eren et al., 2014; Ghosh et al., 2016; Huang et al., 2015b; Lee et al.,
2014; Osada-Oka et al., 2017; Simone et al., 2014a). In accordance, a
null mutation in PAI-1 protects against biological aging in humans
(Arnoldussen et al., 2014; Fukami et al., 2014; Khan et al., 2017; Koh
et al., 2005; Lassila et al., 2007; Srikanthan et al., 2016; Yamamoto
et al., 2014a).
PLAU (urokinase plasminogen activator, also known as uPA), is a
secreted serine protease that converts plasminogen to plasmin and a
direct target of PAI-1 (discussed above). In addition, PLAU directly acts
on the urokinase-type plasminogen activator receptor (uPAR) to induce
intracellular signalling pathways. It is involved in a variety of physio-
logic and pathologic processes, including control of ECM turnover, cell
migration, invasion, cell signalling, blood coagulation, inﬂammation,
cell proliferation, apoptosis, and ﬁbrosis. PLAU activity is directly
controlled by PAI-1 and PAI-1 modulators such as TGFβ family mem-
bers, cortisol and growth factors all contribute to PLAU dysregulation in
various age-related diseases showing impaired tissue regeneration, in-
ﬂammation, and ﬁbrosis (for review see (Sudol, 2011)).
Most importantly, PLAU was directly linked to aging processes and
age-related disease (Miskin and Masos, 1997; Pinsky et al., 2017). It is
expressed and secreted from senescent cells and controls cell pro-
liferation and other processes (Connolly et al., 2010; Cunningham et al.,
2009; Hildenbrand et al., 2008; Hodjat et al., 2013; Hohensinner et al.,
2017; Kortlever and Bernards, 2006; Smith and Marshall, 2010; Wang
et al., 2017f). Overexpression of PLAU in the brain reduces food con-
sumption, causes growth and body weight retardation, accompanied by
an increased lifespan (Miskin and Masos, 1997). PLAU signalling is also
important for inﬂammatory responses. For example, it modulates in-
nate brain inﬂammation (Cunningham et al., 2009), uPAR expression is
elevated during inﬂammation in tissue remodelling and many human
cancers and frequently indicates poor prognosis (Smith and Marshall,
2010). Moreover, inhibition of PLAU/uPAR interaction reveals a role in
suppression of ﬁbrin-associated inﬂammation (Connolly et al., 2010)
and genetic mouse models conﬁrm the important role of PLAU in in-
ﬂammation (Afaloniati et al., 2017; Carmeliet et al., 1993; Pinsky et al.,
2017). PLAU also modulates the p53 pathway explaining its action on
apoptotic, mitochondrial, cell proliferation, and senescence processes
(Hohensinner et al., 2017; Kortlever and Bernards, 2006; Smith and
Marshall, 2010; Wang et al., 2017f). Interestingly, it is highly expressed
and induced by chemotherapy in cancer cells to promote mitochon-
drial-dependent apoptosis (Wang et al., 2017f), whereas in cardio-
myocytes it protects from oxidative stress and apoptosis (Hohensinner
et al., 2017). In cellular senescence, PLAU and PAI-1 are expressed and
shown to mediate doxorubicin-induced senescence (Hodjat et al., 2013;
Kortlever and Bernards, 2006).
In neurodegenerative diseases, genetic variants of PLAU are linked
to the pathogenesis of late onset and sporadic Alzheimer’s disease.
Here, PLAU is involved in processing APP and degrades secreted and
aggregated APP peptides (Ertekin-Taner et al., 2005; Finckh et al.,
2003; Ji et al., 2012). Generally, PLAU is involved in CNS function and
pathology (Cunningham et al., 2009) and, similar action was found in
other organs and tissues. For example, PLAU and PAI-1 are induced in
skeletal muscle injury and contribute to muscle repair (Novak et al.,
2011) and are required for compensatory hypertrophy following sy-
nergistic ablation (DiPasquale et al., 2007; Suelves et al., 2005). In-
creased uPAR expression is associated with complication in diabetes
patients and predicts outcome (Drechsler et al., 2017; Theilade et al.,
2015). In contrast, PLAT has tissue protective eﬀects and is used as anti-
thromboembolic drug in cardiovascular diseases (Hohensinner et al.,
2017; Kunamneni et al., 2008).
We would like to note that both PLAU and PAI-1 have high potential
and are among the best validated prognostic biomarker tests for breast
cancer (Duﬀy et al., 2016; Lampelj et al., 2015). They may be even
interchangeable and it needs to be determined if these molecules are
independently altered and both useful biomarkers for frailty. Never-
theless, in our scoring system PLAU reached high priority, whereas PAI-
1 was medium priority.
MMP7 (matrix metalloproteinase 7, also known as matrilysin), is a
member of MMP family of proteolytic enzymes which are also induced
by the TGFβ pathway. MMPs are involved in ECM remodelling and,
thus, associated with processes such as morphogenesis, angiogenesis,
and tissue repair. Dysregulation of ECM remodelling is associated with
ﬁbrosis, production of inﬂammatory cytokines, as well as endocrine and
exocrine imbalances (Chaturvedi and Hass, 2011), and has been re-
ported in pathologies such as liver cirrhosis, rheumatoid arthritis and
cancer (Gong et al., 2014). As far as MMP7 is concerned, it is expressed
in multiple organs and tissues, including the liver, lung, heart, breast,
spleen, brain, spinal cord, and pituitary gland. It is detected in several
biologic products, and mediates the cleavage of ECM and basement
membrane proteins such as ﬁbronectin, collagen type IV, and laminin
(Gong et al., 2014). Increased MMP7 has been associated with extensive
tissue remodelling and organ dysfunction, particularly in urinary and
respiratory pathologies, with increased plasma and urine levels re-
ported in renal ﬁbrosis (Musial et al., 2015; Zhang et al., 2017a), and
increased levels in plasma (Bauer et al., 2017) and sputum (Guiot et al.,
2017) of idiopathic pulmonary ﬁbrosis patients. Elevated MMP7 ex-
pression has also been demonstrated in several tumours, and was again
associated with ECM remodelling, epithelial-mesenchymal transition
and malignant cells invasion and proliferation in cancers such as
prostate and breast cancer (Chaturvedi and Hass, 2011; Gong et al.,
2014). Furthermore, circulating MMP7 was elevated in individuals with
distant metastases, suggesting a role of this MMP in their development
(Gong et al., 2014).
TGM2 (transglutaminase 2, also known as C polypeptide) is the
most widely distributed member of the transglutaminase family and
catalyses cross-linking of proteins and is expressed in almost all cell
types in the body to varying extents (Gundemir et al., 2012). TGM2 is a
versatile protein, exhibiting multiple enzyme activities, also serving as
a G protein for several transmembrane receptors, acting as a co-receptor
for integrin β1 and β3 and acting as a protein scaﬀold or linker
(Gundemir et al., 2012; Szondy et al., 2017). TGM2 is found in the
ECM, plasma membrane, cytosol, mitochondria, recycling endosomes,
and nucleus, and its subcellular localisation is an important determi-
nant of its function (Gundemir et al., 2012; Tatsukawa et al., 2016).
TGM2 is the most prevalent neuronal transglutaminase (Gundemir
et al., 2012), playing a modulatory role in nervous system development
as well as a regulatory eﬀect on neuronal cell death (Ruan and Johnson,
2007).
The activities of TGM2 have been implicated in diverse pathophy-
siological processes such as wound healing, cell growth, cell survival,
ECM modiﬁcation, apoptosis, and autophagy (Agnihotri and Mehta,
2017), as well as inﬂammation and ﬁbrosis (Szondy et al., 2017). TGM2
has been shown to contribute to ﬁbrosis by ECM accumulation in some
organs. It can promote ﬁbrosis by crosslinking several matrix proteins
making them more resistant to breakdown, and by contributing to TGFβ
formation which in turn has been associated with ﬁbrosis in pathologies
such as cardiac hypertrophy, liver cirrhosis, and renal ﬁbrosis (Szondy
et al., 2017). TGM2 is expressed by human lung ﬁbroblasts, constituting
a positive driver of idiopathic pulmonary ﬁbrosis, a disease char-
acterised by progressive ﬁbrotic destruction of normal lung archi-
tecture, with TGM2 expression levels signiﬁcantly higher in the ﬁbro-
blasts from ﬁbrotic patients compared with controls (Olsen et al.,
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2014). Moreover, TGM2 levels in sputum and plasma were elevated in
patients with COPD (chronic obstructive pulmonary disease) and cor-
related with lung function, pointing to TGM2 as a novel potential di-
agnostic and therapeutic target for COPD (Ohlmeier et al., 2016).
THBS2 (thrombospondin 2), a member of the thrombospondin fa-
mily, is a matricellular protein produced by multipotent mesenchymal
progenitor cells in diﬀerent tissues such as epithelium and endothelium,
connective tissue, cartilage, and bone. It activates latent TGFβ and
plays an important role in the regulation of cell proliferation, apoptosis,
and angiogenesis. THBS2 functions at the interface of the cell mem-
brane and the ECM through its interactions with proteins and pro-
teoglycans, such as collagens, integrins, and ﬁbronectin, to regulate
matrix structure and cellular behaviour.
Overexpression of THBS2 in rodent models and human hyper-
trophied heart causes hypertension and histologic features of interstitial
ﬁbrosis and cardiomyocyte hypertrophy. More recently, it was shown
that heart failure patients with preserved ejection fraction present in-
creased plasma levels of THBS2 and that circulating levels are corre-
lated with disease severity, pointing to THBS2 as an independent pre-
dictor of cardiovascular events and risk of death (Kimura et al., 2016).
THBS2 is also increased in serum of patients with chronic kidney dis-
ease, and was associated with ﬁbrosis and endothelial-mesenchymal
transition in cardiac tissue, placing THBS2, among other antiangiogenic
inhibitors, as a player in the ﬁbrosis-mediated cardiovascular disease
associated with chronic kidney disease (Charytan et al., 2014). THBS2
is additionally involved in systemic sclerosis or scleroderma, an ac-
quired disorder that typically results in ﬁbrosis of the skin and internal
organs. It was observed that increased THBS2 plasma levels deposited
in systemic sclerosis ﬁbroblasts contribute to tissue ﬁbrosis by inducing
collagen expression accompanied by down-regulation of intracellular
THBS2 synthesis due to a negative feedback mechanism preventing
increased extracellular THBS2 deposition and/or tissue ﬁbrosis
(Kajihara et al., 2012).
AGT (angiotensinogen, also known as serpina8), an angiotensin
precursor, is produced by the liver and is converted into angiotensin I
through the action of renin. Angiotensin I is further cleaved by angio-
tensin converting enzyme (ACE) into ATII, the main eﬀector molecule
of RAS. The classical RAS axis has been ampliﬁed with the discovery of
novel enzymes, comprising the novel angiotensin-converting enzyme-
related carboxypeptidase ACE2 and the MAS1 oncogene, which binds
the ATII metabolite angiotensin (1–7), constituting an alternative
pathway axis. The classical RAS axis is closely linked to TGFβ signalling
(Rosenkranz, 2004) and plays a key role in the regulation of systemic
arterial blood pressure, vasoconstriction, water intake, and sodium re-
tention, besides mediating pro-inﬂammatory, pro-thrombotic, and pro-
ﬁbrotic processes, whereas the alternative axis seems to play a pro-
tective role by opposing major ATII actions (Miranda and Simoes,
2017).
ATII (Chang and Wei, 2015), autoantibodies against ATII (Neuman
and Danser, 2018) as well as ACE have been used as markers for various
conditions including cardiovascular (Ikonomidis et al., 2017), liver
(Noguchi et al., 2017) and kidney (Tan et al., 2016) diseases. Serum
concentrations of ACE were associated with impaired myocardial de-
formation and torsion, likely by promoting abnormal collagen turnover
and ﬁbrosis, in never-treated patients with essential hypertension
(Ikonomidis et al., 2017). The predictive value of serum ACE levels in
detecting advanced stages of liver ﬁbrosis as well as initial and inter-
mediate ﬁbrotic stages was also demonstrated, pointing to serum ACE
as an accurate, non-invasive, widely available, and easy method to
evaluate ﬁbrosis related to chronic hepatitis B (Noguchi et al., 2017).
Furthermore, RAS activation was shown to drive the progression of
acute kidney injury and transition from acute to chronic disease stage as
acute kidney injury patients with elevated urinary AGT have been
shown to further progress and present higher mortality rates, sug-
gesting that measurement of urinary AGT could help with identifying
acute kidney injury patients who are at risk of developing accelerated
chronic kidney disease (Tan et al., 2016).
We would also like to note that a controlled balance between tissue
turnover and ﬁbrosis is key for proper tissue functioning. Most of the
molecules mentioned above can be detected in blood or urine and may
be used as biomarkers to determine the level of ﬁbrosis inside the body.
However, veriﬁcation on tissue level needs further studies. Particularly
interesting is the relationship between inﬂammation and ﬁbrosis since
both processes are required for physiological and pathological repair of
tissue injury and are induced by tissue damage. Moreover, inﬂamma-
tion also induces wound healing and ﬁbrosis by activating the wound
healing cascade which leads to ﬁbrosis (White and Mantovani, 2013).
Thus, we believe the crosstalk between two main hallmarks of aging,
namely inﬂammation and ﬁbrosis, would make biomarkers that mea-
sure both, or combinations of biomarkers that measure either one of
them, particularly attractive for diagnosis of frailty and age-related
diseases
In summary, seven candidates, mainly from the TGFβ pathway,
were evaluated for their potential as ﬁbrosis biomarkers for frailty. Two
of the markers reached high priority (AGT, PLAU), and three markers
medium priority (TGFβ, PAI-1, TGM2) and are included in the core and
expanded panel accordingly, whereas MMP7 and THBS2 were con-
sidered low priority.
3.5. NMJ and neurons
Neuronal loss occurs throughout life, particularly after the age of
60, and contributes to brain atrophy, neuroinﬂammation, cognitive
decline in the CNS and loss motor units and impaired NMJ (neuro-
muscular junction) in the PNS (peripheral nervous system) in the el-
derly. In 2001, Paganini-Hill and colleagues (Paganini-Hill et al., 2001)
employed for the ﬁrst time the term cognitive frailty, which was later
operationalised and proposed as an important part of the frailty syn-
drome, being included in the Frailty Index (Fried et al., 2001;
Rockwood et al., 2005). Recently, several cross-sectional and long-
itudinal studies reported the association between physical frailty and
cognitive outcomes in Alzheimer’s disease, vascular dementia, and mild
cognitive impairment (Avila-Funes et al., 2012). The reciprocal asso-
ciation has also been shown, with cognitive impairment being found at
higher rates in frail individuals compared with age-matched controls
(Avila-Funes et al., 2012). In fact, the presence of brain pathologies,
including Alzheimer’s disease, cerebrovascular disease, and Parkinson’s
disease has been associated with a more rapid decline in walking speed
and a quicker progression of frailty (Buchman et al., 2013). The loss of
MUNE was also directly connected to impaired physical function in old
age (Gilmore et al., 2017; McKinnon et al., 2015; McNeil et al., 2005).
Several underlying mechanisms link physical and cognitive frailty,
including cardiovascular and cerebrovascular disease, malnutrition and
metabolic changes, hormonal and growth factor changes and in-
ﬂammation. Cardiovascular risk factors and vascular diseases, such as
myocardial infarction, congestive heart failure, atherosclerosis, and
hypertension contribute simultaneously to physical frailty and to a
higher degree of infarct-like brain lesions that are, in turn, re-
presentative of synaptic loss and neuronal death (Newman et al., 2001).
Vascular comorbidities also impact the NMJ, decreasing the expression
of C-terminal agrin fragment (CAF) and contributing to the age-related
decline in muscle mass and function, also known as sarcopenia, which
has been shown to worsen cognitive decline (Nourhashemi et al., 2002).
Nutritional choices and age-related hormone changes also inﬂuence
late-life cognition (see also the section on hormones). Strong epide-
miological evidence suggests that undernutrition, poor dietary patterns,
low caloric intake and low intake of speciﬁc nutrients increase the risk
to develop dementia (Bollwein et al., 2013; Morley, 2014). A similar
eﬀect is attributed to the age-related decrease in the production of
testosterone (Maggio et al., 2012; Morley, 2014), BDNF (Gezen-Ak
et al., 2013; Liang et al., 2015) and progranulin. These molecules are
thought to be involved in the regulation of neuronal plasticity
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(Nikoletopoulou et al., 2017) and synaptic activity and have also been
show to interfere with Aβ deposition (Maggio et al., 2012; Nigam et al.,
2017) and with the release of inﬂammatory mediators by microglia
cells, the predominant immune cells of the brain. Throughout life mi-
croglia acquire a more reactive phenotype and this active/senescent
phenotype (SASP phenotype) potentiates changes in the expression of
surface receptors such as RAGE (Byun et al., 2012) and the release of
pro-inﬂammatory mediators, including cytokines/cytokine receptors
(IL-6, ST2) (Fu et al., 2016a; Montacute et al., 2017; Yang et al.,
2017b), chemokines (CXCL10, CX3CL1) and complement proteins (C3,
C1q) (Hong et al., 2016), while decreasing the expression of anti-in-
ﬂammatory cytokines and growth factors such as BDNF and pro-
granulin (Gezen-Ak et al., 2013; Lui et al., 2016). This shift compro-
mises microglia’s phagocytic activity and potentiates neuronal damage
both directly, through the neurotoxic activity of inﬂammatory media-
tors, and indirectly, by perturbing microglia contribution to synaptic
maintenance and neuronal homeostasis (Lui et al., 2016).
Taken together, age-related neuroinﬂammatory, vascular, and me-
tabolic changes can have a tremendous impact in neuronal circuits,
worsening cognitive performance and potentiating neurodegenerative
diseases, such as age-related dementias, neuropsychiatric disorders, or
depression (Lee et al., 2012b; Mezuk et al., 2012), which are considered
both risk factors and consequences of frailty. In this context, several
proteins have been recognised as potential biomarkers of neuronal and
NMJ damage and cognitive impairment. We have focused on the seven
“neuron and NMJ” proteins discussed below (see Tables 5,8, S1 and
Figs. 3–5).
BDNF (brain derived neurotrophic factor) is expressed in many
tissues, including the nervous, musculoskeletal, respiratory, cardiovas-
cular, urinary and reproductive systems and can be found in serum and
plasma as well as in activated immune cells. This protein is known to
regulate several aspects of neuronal development and function (Huang
and Reichardt, 2001), such as survival and diﬀerentiation of diﬀerent
neuronal populations, synaptic transmission and plasticity and neu-
ronal repair following injury. BDNF has also been described to con-
tribute to glucose and energy homeostasis, food intake and body weight
control (Willer et al., 2009) and exerts its roles mainly through the
binding and activation of tyrosine kinase B receptor (Bartkowska et al.,
2007) and consequent activation of three main pathways: PLC (phos-
pholipase C), Akt (protein kinase B) and MAPKs (Mitogen-activated
protein kinases). Downstream of these regulators, the main activities of
BDNF are mediated by cAMP response element-binding (CREB) (Tao
et al., 1998) and mammalian target of rapamycin (mTOR). There are
several mouse models available for BDNF full or partial knockout.
Homozygotes for targeted null alleles exhibit sensory neuronal loss that
impact coordination, balance and hearing. These models present post-
natal lethality, strengthening the important role of BDNF during neu-
ronal development.
BDNF is also an important modulator of inﬂammation (Gezen-Ak
et al., 2013; Liang et al., 2015) and autophagy (Nikoletopoulou et al.,
2017; Wu et al., 2017a) and also presents important anti-oxidant
properties (Wu et al., 2017a; Wu et al., 2016a), contributing to increase
mitochondria performance and to mitigate neuronal metabolic defects
following injury (Xu et al., 2017e). High BDNF plasma levels were also
found to correlate positively with successful aging in a Malaysian co-
hort (Lau et al., 2017). On the other hand, BDNF expression is reduced
in the brain of Alzheimer’s disease, Parkinson’s disease and Hunting-
ton’s disease patients. A decrease in BDNF serum levels has also been
reported in mild cognitive impairment (Shimada et al., 2014) and
Alzheimer’s disease patients (Siuda et al., 2017), correlating with lower
cognitive test scores. In addition, BDNF has been identiﬁed in circu-
lating vesicles with neuronal origin. Moreover, in the Baltimore Long-
itudinal study of Aging, participants with walking speed decline had
higher levels of BDNF in neuron-derived vesicles than non-decliners,
while no diﬀerences were observed BDNF levels in plasma or total ex-
tracellular vesicles (Suire et al., 2017).
In musculoskeletal diseases, with a strong inﬂammatory component,
BDNF is increased in some tissues and decreased in others. While BDNF
plasma levels were signiﬁcant higher in knee osteoarthritis patients
with respect to controls, the synovial ﬂuid BDNF levels were lower than
in controls (Pedard et al., 2018). In addition, in a rat model of adjuvant-
induced arthritis, the animals presented lower brain BDNF levels, but
an increase in BDNF serum levels (Simao et al., 2014).
Contradictory results have been found in type 2 diabetes patients.
One study reports a decrease in plasma BDNF levels, which inversely
correlates with fasting glucose levels and insulin resistance (Krabbe
et al., 2007), while two other studies reported an increase in BDNF
levels, showing a positive correlation with percentage of body fat, tri-
glyceride levels, fasting glucose levels and insulin resistance (Boyuk
et al., 2014; Suwa et al., 2006). Despite this, BDNF has been con-
sistently shown to be decreased in atherosclerosis (Casas et al., 2017)
and stroke (Lasek-Bal et al., 2015). In particular, reduction in BDNF
levels in the acute phase of stroke is related to poor outcomes. So far,
several interventions have been shown to increase BDNF levels, in-
cluding exercise (Gomes et al., 2014), cerebrolysin (Alvarez et al.,
2016), estradiol (Numakawa et al., 2014), and metformin (Yoo et al.,
2011).
Agrin (AGRN) is a secreted neuroprotein essential for the formation
and stabilisation of synapses, in particular NMJ. Here, agrin activates
clustering of nicotinic acetylcholine receptors via MusK/Lrp4 (Muscle-
Speciﬁc Tyrosine-Protein Kinase Receptor/ LDL Receptor Related
Protein 4) signalling to improve nerve-muscle connection (Bezakova
and Ruegg, 2003; Burden, 1998; Campagna et al., 1997; Glass et al.,
1996; Kim et al., 2008a; Zhang et al., 2008). The important role of agrin
at the NMJ is further proven as genetic mutations or antibodies against
agrin induce myasthenia gravis (MG) and agrin-deﬁcient mice present
with loss of synapses (Gautam et al., 1999, 1996; Karakaya et al., 2017;
Rimer, 1998; Yan et al., 2018). Cleavage by neurotrypsin or MMP3
inactivates agrin and the c-terminal fragment of agrin (CAF) indicates
NMJ turnover and, thus, is explored as circulating biomarkers for
neuromuscular diseases (VanSaun and Werle, 2000). Indeed, CAF levels
are explored as frailty biomarker in humans.
Moreover, agrin is expressed in various tissues and also non-neu-
ronal cell types such as brain, eye, heart, liver, kidney, lung, and
Schwann cells. In accordance, non-synaptic actions have also been de-
scribed, for example, on immune cells and by binding to TGF-β family
members and β−amyloid (Banyai et al., 2010; Jury and Kabouridis,
2010; Reif et al., 2007; Trautmann and Vivier, 2001; Yang et al., 2001;
Zhang et al., 2008). Actually, agrin was found to be regulated in a
variety of disease conditions, such as diabetes, cardiovascular, kidney,
muscle wasting, immunologic, lung, and neurodegenerative diseases as
well as osteoarthritis, kidney, nerve, and brain injury and subsequently
explored as biomarker (Donahue et al., 1999; Drey et al., 2013; Falo
et al., 2008; Gros et al., 2014; Hettwer et al., 2013; Rauch et al., 2018;
Steubl et al., 2016; Verbeek et al., 1999). Indeed, agrin seems to be a
predictive marker in various degenerative diseases and is also being
explored as a therapeutic intervention in neuromuscular diseases and
muscular dystrophies (Hettwer et al., 2014; Li et al., 2018a; Rudolf
et al., 2014).
Proganulin (PGRN) is a growth factor which is expressed in many
tissues, including epithelia, bone marrow, immune cells and solid or-
gans, where it plays multiple roles, from wound healing and tissue re-
pair to cell proliferation (Kwack and Lee, 2017) and migration, tu-
morigenesis, cartilage development/degradation, and neuronal
survival. Progranulin is mostly associated with the secretory pathway
and can be found in plasma and cerebrospinal ﬂuid and also in secreted
exosomes. In fact, loss of progranulin leads to a reduction in the number
of exosomes and alters exosome composition (Benussi et al., 2016).
Progranulin is cleaved by extracellular proteases into eight diﬀerent
granulin domains, which present distinct and sometimes contrary roles
to progranulin. Several mouse strains modulating progranulin are
available, including full knockout and heterozygous lines. Knockout
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display enhanced macrophage function, reproductive and behavioural
abnormalities and premature death with increased cellular aging.
Progranulin has been considered to be an anti-inﬂammatory protein
(Ma et al., 2017) and, in this context, its activity is thought to be
mediated by TNF-α receptor and β-catenin. Progranulin loss has been
observed in several dementias (Fardo et al., 2017), such as Alzheimer’s
disease and Frontotemporal lobar degeneration, as well as after acute
brain injury, contributing to an increase in the expression of pro-in-
ﬂammatory genes, to excessive microglia activation (Ma et al., 2017),
and to autophagy impairment (Chang et al., 2017b; Xu et al., 2017a).
On the other hand, plasma and cerebrospinal ﬂuid progranulin levels
are thought to increase during healthy aging (Ma et al., 2017; Nicholson
et al., 2014) and have also been found to be increased in MS patients
(Vercellino et al., 2011). The anti-inﬂammatory role of progranulin has
been reported in cardiovascular diseases. Here, it augments vasor-
elaxation and reduces ischemia-reperfusion injury (Korolczuk and
Beltowski, 2017). In addition, it protects against inﬂammatory reac-
tions underlying atherosclerosis, being strongly expressed in foam cells
of atherosclerosis plaques (Kawase et al., 2013). Progranulin is highly
expressed in macrophages and loss in these cells leads to increased
cholesterol levels and altered high-density lipoprotein-associated pro-
teins (Yoo et al., 2013) which regulate insulin resistance (Zhou et al.,
2015a). An increase in progranulin leads to insulin resistance and
overall mitochondrial dysfunction and apoptosis in mice adipocytes
(Guo et al., 2017). Circulating progranulin is increased in obesity (Zhou
et al., 2015a), whereas progranulin deﬁciency protects from high fat
diet-induced insulin resistance. There is a strong association between
progranulin and type 2 diabetes and its complications, in particular
microangiopathies (Xu et al., 2017a; Zhou et al., 2015a).
In osteoarthritis, progranulin plays a protective role by antagonising
inﬂammatory mediators, protecting against cartilage defects and sup-
porting osteoblast diﬀerentiation (Abella et al., 2016; Wang et al.,
2016b; Zhao et al., 2015). In rheumatoid arthritis, the progranulin/
TNF-α ratio was shown to correlate with the severity of disease, while
the serum concentration of progranulin was found to be above healthy
controls (Yamamoto et al., 2014b). Several compounds have been
shown to revert the eﬀects caused by progranulin loss and to modulate
progranulin levels. The histone deacetylase inhibitor Vorinostat (also
known as SAHA), the anti-malaria agent chloroquine, and the kinase
inhibitors selumetinib and MEK162 are able to prevent TDP-43 (TAR
DNA-binding protein 43) accumulation in progranulin-deﬁcient lym-
phoblasts (Alquezar et al., 2015). Additionally, the natural disaccharide
trehalose increases endogenous and extracellular progranulin levels and
has multiple reported neuroprotective properties (Holler et al., 2016).
Despite being increased in some age-related conditions and decreased
in others, its multiple cellular functions and dysregulation across sev-
eral organs make progranulin a good biomarker, particularly in relation
to inﬂammaging and neurodegeneration, where its decrease is con-
sensual.
C3 and C1q (complement factor 3 and 1Q) belong to the comple-
ment cascade of immune system that orchestrates the recognition and
elimination of pathogens and undesirable bodies, such as apoptotic cells
and ineﬃcient synapses (Dunkelberger and Song, 2010). C1q is the
main protein of the classical complement cascade and is composed of
three similar but distinct subunits, i.e., A, B, and C (Sellar et al., 1991).
Following assembly, C1q attaches to the Fc chain of IgG and IgM an-
tibodies which becomes activated by the binding to their respective
antigen. C3 is the dominant protein of the alternative complement
pathway, but also important in the classical cascade and lectin signal-
ling. Following binding, either anaphylatoxins C1a/C3a which are po-
tent pro-inﬂammatory molecules with immune cell functions or opso-
nins C1b/C3b which covalently bind to cell surface proteins, are
produced by a series of cleavages. Ultimately, all these pathways cul-
minate in the formation of the membrane attack complex
(Dunkelberger and Song, 2010).
Both C1q and C3 have been observed to directly correlate with
aging and cognitive decline. C1q levels are upregulated in plasma of
aged individuals (Watanabe et al., 2015) and C3 levels are down-
regulated in the cerebrospinal ﬂuid of subjects presenting fast cognitive
decline (Toledo et al., 2014). In addition, the levels of both these pro-
teins are increased in the brains of patients with neurodegenerative
conditions, such as Alzheimer’s disease, frontotemporal lobar degen-
eration and amyotrophic lateral sclerosis (Hong et al., 2016; Lui et al.,
2016; Sta et al., 2011). In these diseases, C1q and C3 accumulate in
synapses targeted for elimination (Hong et al., 2016; Lui et al., 2016)
and in endothelial cells following cerebral ischemia-reperfusion injury
(Lai et al., 2017).
C1q and C3 accumulation was also observed in other age-associated
diseases unrelated to brain dysfunction. While C1qb is a clinical pre-
dictor (Peters et al., 2017) and C3 a risk factor for type 2 diabetes
(Engstrom et al., 2005), these proteins were also found to be involved in
atherosclerosis, although their role is still controversial. On the one
hand, C1q promotes macrophage survival during ingestion of excess
cholesterol (Pulanco et al., 2017) and, on the other hand, C3 activation
in atherosclerotic lesions by cholesterol crystals induces release of po-
tent inﬂammatory mediators (Niyonzima et al., 2017). Thus, the com-
plement system activation is involved in several age-related pathologies
and could be considered both a biomarker and a therapeutic target for
age-related diseases.
sRAGE (soluble advanced glycosylation end product-speciﬁc re-
ceptor, aka AGER) binds macromolecules formed by glycation, called
advanced glycation end-products (AGEs). AGEs may play a major role
in aging and disease (Brownlee, 1995; Simm, 2013; Simm et al., 2015).
It has been suggested that activation of RAGE may be involved in
diabetes mellitus (Schmidt, 2015), aging, neurological diseases and
some forms of cancer (Ahmad et al., 2017). RAGE belongs to the family
of immunoglobulins and has an extracellular ligand-binding domain
and intracellular domain by which it initiates various age-related sig-
nalling pathways. RAGE activation is involved in inﬂammatory pro-
cesses and DNA damage. sRAGE is a splice variant of RAGE, found in
plasma that lacks the intracellular domain and does not initiate sig-
nalling. sRAGE is described as a decoy receptor which binds and
functionally inactivates AGEs, reducing immuno-inﬂammatory re-
sponses (Wang et al., 2015b) and low sRAGE levels have been asso-
ciated with increased arterial stiﬀness in hypertensive non-diabetic
patients, while sRAGE has been found to be elevated in type I diabetes
and associated with peripheral neuropathy in type II diabetes (Aubert
et al., 2014; Bakker et al., 2015; Mayer et al., 2016). Moreover, sRAGE
concentration is decreased in Alzheimer’s disease patients compared
with healthy controls (Xu et al., 2017d). Alternatively, sRAGE has been
used as a biomarker for certain diseases such acute respiratory distress
syndrome (Jabaudon et al., 2018)) and is also a prognostic biomarker in
patients with sepsis (Brodska et al., 2013).
HMGB1 (high mobility group box 1), is an intracellular, DNA
binding protein, ubiquitously expressed which regulates gene expres-
sion, but can also be released in the event of cellular damage. It is
considered as damage-associated molecular pattern molecule that
triggers inﬂammation and adaptive immune response (Bianchi et al.,
2017) by binding in the extracellular space to an inﬂammatory receptor
such as RAGE, TLR2, and TLR4 (Li et al., 2015a). In addition, HMGB1 is
also a critical regulator of mitochondrial function and morphology
(Tang et al., 2011), cell proliferation (particularly in cancer cells)
(Angelopoulou et al., 2016; Ko et al., 2014) and autophagy. In this
regard, it mediates autophagy in a p53-dependent manner to promote
either tumour-cell survival or cellular senescence in various human
cells (Davalos et al., 2013; Livesey et al., 2012).
Taking this into consideration, it is not surprising that an increase in
HMGB1 levels is observed in neuroinﬂammation following brain in-
juries leading to epilepsy or cognitive dysfunction and can also trigger
and amplify the inﬂammation cascade in ischemic injury (Qi et al.,
2016; Ravizza et al., 2017; Wang et al., 2017a). HMGB1 orchestrates
responses to tissue damage via inﬂammation, innate and adaptive
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immunity, tissue repair, and in sepsis. HMGB1 plasma levels were
found to correlate with the disseminated intravascular coagulation and
organ failure assessment (Bianchi et al., 2017; Hatada et al., 2005;
Stevens et al., 2017). Other diseases with increased HMGB1 levels are
ﬁbrotic kidney disease (Chen et al., 2016a), diabetes (Wu et al., 2016b),
various carcinomas, and gliomas (Angelopoulou et al., 2016; Ko et al.,
2014; Nguyen et al., 2017), rheumatoid arthritis and myocardial in-
farction (Guo et al., 2011; Limana et al., 2005; Qi et al., 2016; Vezzoli
et al., 2011). In heart failure, HMBG1 together with sRAGE are clini-
cally used to assess prognosis and risk stratiﬁcation (Marsh et al.,
2017). Cerebrospinal ﬂuid HMGB1 is associated with neuronal death in
subarachnoid haemorrhage (Wang et al., 2017a).
Interestingly, serum levels of HMGB1 were shown to signiﬁcantly
decrease with age in humans (Fu et al., 2016b), which contrasts the
detrimental eﬀects of elevated HMGB1 in so many pathologic condi-
tions. Moreover, studies with the senescence inhibitor metformin
showed that it directly binds HMGB1 and inhibits its pro-inﬂammatory
activity (Horiuchi et al., 2017). Inhibition of HMGB1 is also pursued as
a therapeutic target in Sjoergren’s syndrome, experimental sepsis,
gastric cancer, and epilepsy with attenuating and in some cases even
disease-modifying activity (Chung and Lim, 2017; Kim et al., 2017b;
Stevens et al., 2017; Zhao et al., 2017b).
ST2 (soluble suppression of tumorigenicity 2), is a member of the IL-
1 receptor family also known as IL-33 receptor. It has been linked to
inﬂammation potentiating the response of macrophages to LPS stimulus
in a TLR4/MyD88-dependent pathway (Espinassous et al., 2009). In
addition, following IL-33 binding, ST2 actively co-stimulates T-cell re-
sponses, enhancing the diﬀerentiation of diverse T-cell subsets, in-
creasing clonal expansion and triggering antigen-independent cytokine
production (Peine et al., 2016). Although no report has directly asso-
ciated ST2 with aging, several studies implicated this molecule in age-
related diseases such as type 2 diabetes or cardiovascular disorders
(Griesenauer and Paczesny, 2017). Increased production of ST2 has
been implicated in type 2 diabetes (Miller et al., 2012), as well as in
cardiovascular injury (Wang et al., 2018a) with ST2 being considered a
predictor of severity in ventricular cardiomyopathy (Broch et al., 2017)
and of cardiovascular mortality in haemodialysis patients (Zhang et al.,
2017c). Further, ST2 has also served as a prognostic biomarker fol-
lowing acute stroke (Wolcott et al., 2017) and associated with sub-
clinical brain injury and cognitive impairment (Andersson et al., 2015).
Interestingly, serum levels of ST2 are higher in rheumatoid arthritis
patients than in healthy controls and are decreased following treatment
with conventional disease-modifying antirheumatic drugs (Hong et al.,
2011). Finally, increased levels of ST2 predict mortality risk in critically
ill patients (Krychtiuk et al., 2018), making it a potential candidate as a
frailty biomarker.
In summary, seven biomarker candidates with activity on NMJ and
neurons were evaluated. We identiﬁed two high priority markers
(progranulin, BDNF) which will be included in the core panel, and ﬁve
medium priority markers (agrin, C3/C1q, sRAGE, HMGB1, and ST2) for
the expanded panel. Many of the markers in this section are closely
linked to inﬂammation and could be easily discussed in the in-
ﬂammation section (3.1).
3.6. Cytoskeleton and hormones
Actin cytoskeleton is a cellular component whose role has been
vastly underestimated for a long time and now is recognised as essential
factor in various cellular functions, in particular for cell morphology.
For instance, it is vital for the signalling networks that link cellular
processes such as polarisation, organelle movement, motility, and di-
vision to environmental signals. Also, oxidative stress can damage the
actin cytoskeleton which may lead to apoptosis (Amberg et al., 2012).
Thus, it is not surprising that cytoskeleton seems to have an important
role in age-related diseases and aging (for review see (Rao and Cohen,
1990)).
The cytoskeleton is controlled by a variety of hormones which are
regulated on their part in a complex manner such as production of pro-
hormones in the hypothalamus, which induce the secretion of hor-
mones from the pituitary gland, also called hypothalamus pituitary
axis. Subsequently, pituitary hormones are circulating and aﬀect the
production of, adrenal, gonadal, thyroid, somatotropic, and prolactin
hormones elsewhere in the body. These hormone cascades are regulated
by positive and negative feedback loops and are, therefore, changing
rapidly and aﬀect each other’s production and release. The dysregula-
tion of hormones in aging is well established (for review see (Maggio
et al., 2010)) and conﬁrmed in many studies on caloric restriction (De
Loof et al., 1996), an intervention that increases lifespan in organisms
ranging from yeast to mammals. Indeed, in most organisms, the eﬀect
of caloric restriction correlates with alterations in insulin/IGF-1 path-
ways suggesting that hyperglycaemia and hyperinsulinemia are accel-
erating aging. GH)/IGF-1 signalling molecules have been linked to
longevity including their homologues in other species and IGF-I in-
hibition was shown to increase lifespan. Overall, the life-prolonging
eﬀects of caloric restriction correlated well with lowered IGF-1 levels.
Not only hormones of the GH/IGF-1/Insulin pathways, but also mem-
bers of other pathways such as mTOR, NAD+, Sirtuin, P53, α-klotho/
FGF23, FGF21, and apolipoprotein (APOE) pathways have been linked
to age-related diseases such as cancer, cardiovascular disease, diabetes,
osteoporosis, and neurodegenerative diseases. Actually, it is now be-
lieved that hormones directly inﬂuence health during aging and re-
present key targets in anti-aging therapy such as α-klotho and ghrelin.
For example, ghrelin or synthetic agonists are used as interventions to
increase appetite and muscle mass in frailty and in frailty-associated
disorders. Moreover, most hormones are easily detectable in serum and
urine and may be good predictors of biological aging and subsequently
frailty and here we nine “hormone” markers (see Tables 6,8, S1 and
Figs. 3–5). We would like to note that we intentionally did not include
sex hormones in our frailty biomarker panels even though reduced le-
vels are reported in aged and frail people and replacement therapy is
pursued as therapeutic intervention. There are many reports and re-
views in this area (see (Horstman et al., 2012; Samaras et al., 2014))
and our aim was to focus on sex-independent hormones and bio-
markers.
GH (growth hormone also known as somatotropin) is a somato-
tropic peptide hormone that stimulates growth, cell reproduction, and
cell regeneration in humans and laboratory animals. GH secretion is
regulated by the hypothalamic hormone Gonadotropin-releasing hor-
mone (GnRH) in a pulsatile proﬁle with a strong dependence on sleep/
waking and fasting. GH also stimulates, through the JAK-STAT signal-
ling pathway, the production of IGF-1. It is therefore assumed that GH
exerts its eﬀects mainly through IGF-1 which will be discussed in more
detail below. Actually, replacement therapy with GH in frailty and
other age-related conditions was ﬁrst proposed a very long time ago
(Hodes, 1994; Villareal and Morley, 1994). Moreover, there is a strong
correlation between the levels of the hunger hormone ghrelin, also
discussed below, GH, and IGF-1 (Arellanes-Licea Edel et al., 2014).
IGF-I (insulin-like growth factor 1) is a member of a peptide family
that promotes growth and development during foetal and postnatal life.
Although the IGF-1 gene is ubiquitously expressed in the body, it is
mainly produced in the liver. Transgenic ablation and disruption of this
gene results in reduced lifespan and severe growth retardation. In ad-
dition, absence of IGF-I in mice results in generalised organ hypoplasia,
including underdevelopment of the CNS and defects in muscles, bones,
and the reproductive system. Studies have shown that IGF-1 plays
crucial roles at the molecular level in many processes such as nucleic-
acid activation, carbohydrate, lipid and protein metabolism, cellular
organisation and homeostasis, cell diﬀerentiation, cellular senescence,
and apoptosis. Furthermore, IGF-I is also involved in variety of phy-
siological and pathophysiological conditions such as immune system
processes, inﬂammation, mitochondrial dysfunction, tumour develop-
ment, frailty, aging, and age-related diseases. For example, it was
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reported that insulin/IGF-1 cross talk and IRS-1 (insulin receptor sub-
strate 1) phosphorylation is responsible for longevity in Ames dwarf
mice (Bartke and Darcy, 2017; Dogan et al., 2011; Handayaningsih
et al., 2012; Jia et al., 2018; Lara-Diaz et al., 2017; Mathew et al., 2017;
Olleros Santos-Ruiz et al., 2017; Papaconstantinou and Hsieh, 2015).
Moreover, elevated serum IGF-I was reported in both humans and an-
imals with increased body weight and adipose tissue. In addition, de-
creased IGF-I was reported after caloric restriction (Dogan et al., 2011,
2017). Interestingly, while caloric restriction signiﬁcantly decreased
IGF-I levels detected in mice at 25, 37 and 55 weeks of age, no changes
were found at earlier (week 13 or 14) or at later (week 74) age (Dogan
et al., 2011). Various mouse models are available to study the IGF-I
gene in vivo. While homozygote mutants are viable, fertile, and normal
in size, homozygous null mutants are severely growth retarded and die
perinatally due to immature organ systems. Moreover, partial knockout
mice show growth retardation and abnormalities in selected organs.
α-Klotho (α-KL) is a transmembrane protein related to beta-gluco-
sidases which controls organism sensitivity to insulin and plays a cru-
cial role in cellular homeostasis (e.g. carbohydrate and protein meta-
bolism). It interdependently works with FGF23 (discussed below) with
α-klotho mainly functioning as a co-receptor for FGF23 signaling.
Actually, α-klotho is one of the proteins with the most clear association
with aging and was originally identiﬁed as putative aging-suppressor
gene and signiﬁcantly contributed to the advanced understanding of
aging processes. In mice, overexpression of α-klotho signiﬁcantly ex-
tends lifespan, whereas knockdown causes a progeroid phenotype with
markedly shortened lifespan (Xu and Sun, 2015). Moreover, serum α-
klotho declines with age and in patients with chronic renal failure,
where it is suggested to be one of the factors underlying degenerative
processes (e.g., atherosclerosis, osteoporosis, and skin atrophy) seen in
the condition. Also, mutations within this protein have been associated
with aging and bone loss. α-klotho is expressed at the highest levels in
kidney and brain. In the brain, expression is found in cerebellum and
hippocampus, in microglia, oligodendrocytes, and neurons. α-Klotho
can be detected in circulation after shedding of the amino-terminal
extracellular domaine (Abraham et al., 2016; Baldan et al., 2015;
Bartali et al., 2013; Bian et al., 2015; Buendia et al., 2015; Fan and Sun,
2016; Guo et al., 2018; Hu et al., 2011; Kim et al., 2015a, d; Lin and
Sun, 2015; Saito et al., 1998; Sopjani et al., 2015; Xu and Sun, 2015;
Zhou and Wang, 2015).
FGF23 (ﬁbroblast growth factor 23, also known as phosphatonin) is
a pleiotropic protein of the endocrine FGF sub-family secreted by os-
teocytes where it negatively regulates the plasma phosphate levels by
acting on the kidneys. For its biologic actions, FGF23 requires α-klotho
as co-receptor (see above). Secretion of FGF23 is tightly regulated by
various factors, including α-klotho, PTH (parathyroid hormone), vi-
tamin D, phosphate, and calcium and both genetically increased (au-
tosomal dominant hypophosphatemic rickets) and decreased FGF23
activity (familial tumoural calcinosis) induce pathologies. Interestingly,
α-klotho induces FGF23 causing increased FGF23 levels in conditions
with low α-klotho which are believed to have mainly detrimental ef-
fects, such as in kidney and cardiovascular disease as well as aging, CNS
disorders, osteoporosis, rheumatoid arthritis and diabetes. Indeed, in-
creased FGF23 levels predict death and mortality in various diseases
(Kuro, 2017; Langsford et al., 2017). Therefore, in contrast to α-klotho
supplemention, inhibition of FGF23 is being explored as a therapeutic
approach for kidney and other diseases with increased FGF23 levels.We
would like to note that α-klotho or FGF23 are interchangeable as
markers for the phosphate/vitamin D pathway and that they are often
changed in opposite ways in age-related diseases as reduced α-klotho
leads to a compensatory increase in FGF23 which seems to have mainly
detrimental eﬀects (Akhabue et al., 2018; Atta et al., 2016; Avtanski
et al., 2016; Cavalli et al., 2012; Claramunt-Taberner et al., 2018;
Clinkenbeard and White, 2017; Econs, 2017; Erben, 2017, 2018;
Francis and David, 2016; Fukumoto, 2018; Hanudel et al., 2016; He
et al., 2018; Hyun et al., 2018; Kanbay et al., 2017; Kutilek, 2017;
Pastor-Arroyo et al., 2018; Rossaint et al., 2017; Ruppe et al., 2016).
FGF21 (ﬁbroblast growth factor 21) is mainly known as an hepa-
tokine regulating sugar intake via the central nervous system. However,
it also has pleiotropic action as adipokine, mitokine, myokine, and
neuroendocrine (Matuszek et al., 2010). FGF21 uses β-klotho as a co-
receptor leading to distinct action from FGF23 even though both signal
via FGF receptors. In contrast to α-klotho, β-klotho (Xu and Sun, 2015)
is not extensively studied in the context of age-related diseases or frailty
and, thus, is not considered a candidate for biomarkers of frailty.
Moreover, FGF21 is also involved in many cellular activities, including
mitosis and viability and is generally induced by mitochondrial-de-
pendent mechanims. Therefore, its role as potential biomarker of mi-
tochondrial diseases together with GDF15 has been broadly explored
and FGF21 could also be discussed in the mitochondria section.
Beside mitochondrial diseases it is modulated and used as potential
biomarker in various diseases, such as metabolic syndrome, diabetes,
sepsis, musculoskeletal, renal, cardioavascular, ocular, and liver dis-
orders as well as osteoarthritis, rheumatoid arthritis and cancer.
Interestingly, many pathologies are aggrevated by FGF21 deletion as,
for example, those induced by diabetes. There is also a link to pre-
mature aging and lifespan. In addition, FGF21 may predict mortality
and protects against hepatotoxicity induced by acetaminophen.
Actually, various long-acting and engineered FGF21 variants are ex-
plored in cardiovascular and metabolic diseases and FGF21 is induced
by metformin, an agent also explored in age-related diseases, including
frailty (Bartali et al., 2013; Davis et al., 2017, 2013; Davis et al., 2016;
Domouzoglou et al., 2015; Dong et al., 2015; Dushay et al., 2010;
Hsuchou et al., 2007; Hulejova et al., 2012; Itoh, 2014; Kohara et al.,
2017; Lee et al., 2015a, a; Lehtonen et al., 2016; Li et al., 2018c; Liu
et al., 2014b; Lovadi et al., 2017; Mai et al., 2011; Morovat et al., 2017;
Planavila et al., 2013; Scholle et al., 2018; Shi et al., 2018; Stein et al.,
2010; Suomalainen et al., 2011; Talukdar et al., 2016; Woo et al., 2013;
Ye et al., 2014, 2017a; Zagarskikh et al., 2018; Zhang et al., 2012).
Resistin (RETN) is a circulating factor, primarily secreted by white
adipose tissue in mice and monocytes in humans (Al Hannan and
Culligan, 2015). It has also been detected in human placenta, skeletal
muscle, small intestine, spleen, stomach, thymus, thyroid gland, and
uterus. Resistin plays a role in many pathways, such as inﬂammation
(Demirci et al., 2017; Edwards et al., 2013; Meng et al., 2017; Shen
et al., 2014; Zuniga et al., 2017), cell proliferation (Mohammadi et al.,
2017; Singh et al., 2017), apoptosis (Lu et al., 2013; Zhu et al., 2017a)
and mitochondrial function (Wen et al., 2018, 2015a; Zhou et al.,
2013). Resistin also contributes to insulin and leptin resistance asso-
ciated with reduced brown adipose tissue activity (Asterholm et al.,
2014). Increased serum resistin levels were reported in adult and older
persons with heart failure and cardiovascular diseases such as coronary
artery disease, coronary syndrome, and peripheral arterial disease
(Butler et al., 2009; Codoner-Franch et al., 2014; Gencer et al., 2016;
Hsu et al., 2017a; Li et al., 2013; Wang et al., 2017e). Importantly, the
adiponectin/resistin index is suggested to be even more strongly asso-
ciated with atherosclerosis (Rubio-Guerra et al., 2013). Resistin has also
been explored as a biomarker (for more details on adiponectin see
below) in many other age-related diseases, including rheumatoid ar-
thritis (Sato et al., 2017), osteoarthritis (Song et al., 2016a), neurolo-
gical diseases (Dong et al., 2017b, 2010; Sawicka et al., 2017; Zanardini
et al., 2018), metabolic diseases (Menzaghi et al., 2014; Solis-Cano
et al., 2017; Wen et al., 2014), and various types of cancer (Georgiou
et al., 2016; Hsieh et al., 2014; Kallio et al., 2017; Lee et al., 2016b;
Vallega et al., 2016). In accordance, homozygous resistin null as well as
mutant mice are available and present obesity, insulin resistance, as
well as immunologic and inﬂammation phenotypes.
Adiponectin (ADIPOQ) is another adipokine secreted from adipose
tissue and circulating as hormone in the blood. Adiponectin is de-
creased in various pathologic conditions such as obesity, diabetes, and
coronary artery disease (Hotta et al., 2000; Kumada et al., 2003). In
serum, three diﬀerent adiponectin forms are distinguished: trimer,
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hexamer, and a high molecular weight high molecular weight adipo-
nectin form (Ouchi et al., 2003) and these forms are diﬀerentially
modulated in disease conditions
Adiponectin modulates various “hallmark of aging” mechanisms
including inﬂammation, mitochondrial function, apoptosis, and cell
proliferation. For example, It protects cells from inﬂammation, reduces
cytokine secretion and inhibits NFκB signalling and is being explored as
inﬂammation biomarker (Awazawa et al., 2011; Cong et al., 2007;
Dieudonne et al., 2006; Gong et al., 2016; Iwabu et al., 2010; Kang
et al., 2005; Kim et al., 2011; Kobashi et al., 2005; Kobayashi et al.,
2004; Liu et al., 2016b; Ma et al., 2002; Maeda et al., 2002; Ouchi et al.,
2000; Zhao et al., 2017c). In accordance, adiponectin preserves insulin
sensitivity via IL-6 signalling and adiponectin knockout mice show in-
creased beta-oxidation and TNF-α levels in muscle and liver tissue
(Berryman et al., 2004; Chen et al., 2017a; de Luis et al., 2016; Kubota
et al., 2002; Ma et al., 2002; Maeda et al., 2002; Ohashi and Funahashi,
2006; Ortega Moreno et al., 2016; Ryo et al., 2004).
In various cancer cell lines adiponectin inhibits proliferation, ER
stress, or induces apoptosis (Huang et al., 2015a; Karaduman et al.,
2007; Korner et al., 2007; Mantzoros et al., 2004; Miyoshi et al., 2003).
In aging, high molecular adiponectin form, but not total adiponectin is
changed, and in long-lived animals plasma adiponectin are elevated
(Bartke, 2016; Combs et al., 2004; Miller et al., 2017; Sun et al., 2013;
Wang et al., 2007b). Moreover, high adiponectin levels are associated
with decreased risk for myocardial infarction and exercise also has a
positive eﬀect on adiponectin, whereas low levels are associated with
cancer and dysfunctions in various organs such as liver, ears, muscle,
and many more (Ambroziak et al., 2018; Fujishima et al., 2017; Niinaga
et al., 2016; Pischon et al., 2004; Sattar et al., 2006; von Eynatten et al.,
2006a).
Thus, it is not surprising that adiponectin has been explored as a
biomarker in various diseases including hepatitis C, various cancers,
inﬂammation, renal disease, atherosclerosis, and migraine and is also
being directly pursued as therapeutic intervention target (Chen et al.,
2015b; Kelesidis et al., 2006; Liu et al., 2017a; Nawrocki et al., 2006;
Otani et al., 2010). There is a tremendous amount of knowledge around
adiponectin and it has great potential as diagnostic, prognostic and
therapeutic biomarker for frailty.
Leptin (LEP) is another circulating adipokine mainly produced by
adipocytes, but also expressed in various other tissues, such as cardio-
vascular, reproductive, liver, musculoskeletal and neurons. The major
role of leptin is control of body weight and energy expenditure. In
addition, leptin regulates diﬀerent physiological and pathophysiolo-
gical processes including apoptosis, angiogenesis, cell proliferation,
energy metabolism, inﬂammation, diabetes, reproduction, obesity, and
diﬀerent kinds of tumour development (Dogan et al., 2010; Ray and
Cleary, 2017; Ryan et al., 2003; Silha et al., 2006; Xu et al., 2017c).
There is also clear evidence for the role of leptin in aging and age-
related diseases. For example, leptin was reported to contribute to
worsening the prognosis of tumoral and neurodegenerative processes
by increasing the susceptibility of cells to inﬂammatory mediators
(Martin et al., 2017b). In animal studies serum leptin increased with
aging (Dogan et al., 2017) and caloric restriction led to opposite eﬀects.
It should also be noted that there is some controversy as several studies
reported no eﬀects of caloric restriction on serum leptin levels both in
human and animals (Ryan et al., 2003; Silha et al., 2006). Regarding
mouse models, both leptin and leptin receptors knockout mouse models
are available and used as models for obesity and diabetes as they gain
weight rapidly. They also have potential as age-related disease and
frailty models as they have a metabolic syndromes and more im-
portantly shortened lifespan.
Leptin similar to adiponectin modulates various “hallmark of aging”
mechanisms including inﬂammation, mitochondrial function, apop-
tosis, cellular senescence and cell proliferation and there is a lot of
knowledge available around this ubiquitously expressed and modulated
factor. In the following, only a few examples are given and we
otherwise refer to previous reviews on the action of leptin and its po-
tential as biomarker and therapeutic target (de Candia and Matarese,
2017; Mao et al., 2018; McGregor and Harvey, 2017; Pan and Myers,
2018; Ramos-Lobo and Donato, 2017; Ray and Cleary, 2017; Rehman
et al., 2017; Tsai, 2017). For example, it is noteworthy that leptin ex-
acerbates sepsis-mediated morbidity and mortality (Shapiro et al.,
2010), mediates muscle- and liver-derived IGF-1 in aged mice (Hamrick
et al., 2015), is important for musculoskeletal health (Philbrick et al.,
2018, 2017; Yu et al., 2017a) and body composition (Denroche et al.,
2011; Xiang et al., 2018). Moreover, leptin and analogues are used
therapeutically in lipodystrophy (Muniyappa et al., 2017).
Ghrelin (GHRL) is a small peptide hormone, secreted mostly from
the fundus of the stomach, intestines, pancreas, and hypothalamus,
which plays a major role in the regulation of appetite and metabolism.
The ghrelin peptide presents a carbon fatty acid linked through an ester
bond to serine 3. Although, most ghrelin found in circulation is in the
unacylated form (UnAG), only the acylated (AG) peptide is able to bind
to the ghrelin receptor (also called growth-hormone-secretagogue re-
ceptor 1a), eliciting multiple biological eﬀects, such as: 1) increase in
appetite, 2) increase in food uptake, 3) modulation of glucose home-
ostasis and insulin sensitivity and 4) increase in GH release. Mice
homozygous for most disruptions in the ghrelin gene display age-de-
pendent changes in stimulated food intake and metabolism.
In addition to its orexigenic and GH releasing functions, AG-medi-
ated signalling has been associated with an increase in gastric motility
and an increase in lean body mass and has been shown to promote
adipogenic and anti-inﬂammatory eﬀects on monocytes and T-lym-
phocytes (Dixit et al., 2004). On the other hand, UnAG is reported to
also have important physiological roles that are independent from the
ghrelin receptor and sometimes even oppose AG activity, such as: 1)
enhancement of pancreatic β-cell survival and function and 2) im-
provement of cardiovascular activity and regulation of carbohydrate
metabolism. UnAG has been shown to rescue mitochondria damage
following ischemia/reperfusion injury in the liver (Rossetti et al.,
2017), while treatment with AG normalised chronic heart failure-as-
sociated skeletal muscle mitochondrial dysfunction and pro-in-
ﬂammatory changes, showing a potential positive impact in heart
failure patients (Barazzoni et al., 2017). Ghrelin treatment was also
shown to reduce intestinal mucosa injury and vascular calciﬁcation
through stimulation of autophagy (Wan et al., 2016; Xu et al., 2017b),
Ghrelin also mediates additional beneﬁcial eﬀects through stimulation
of cell proliferation, inhibition of apoptosis (Liao et al., 2017) and a
decrease in ﬁbrosis (PMID: 46313288).
Concerning its direct action in aging, some controversy can be found
in the literature. While several studies point to a relation between low
ghrelin levels and higher weight loss and poorer hand grip strength in
the elderly, longevity is not directly aﬀected by ghrelin deletion.
Despite this, treatment of wildtype and ghrelin knockout mice with
ghrelin increases food intake, body weight, and muscle strength, which
suggests that ghrelin can be used as an intervention to protect against
some age-related disorders (Guillory et al., 2017). In this context,
ghrelin levels and ghrelin administration were tested in three diﬀerent
models of accelerated or normal human aging. Elevated plasma ghrelin
levels were observed in both α-klotho-deﬁcient and senescence ac-
celerated mice. Nevertheless, ghrelin administration failed to stimulate
appetite and prolong survival in α-klotho-deﬁcient mice, while ghrelin
signalling potentiators were able to decrease microglial activation and
prolong survival in all three animal models tested in this study
(Fujitsuka et al., 2016). In humans, AG levels were shown to be in-
creased in patients with mild cognitive impairment, in association with
poorer language skills and defected long and short-term memory, in
type II diabetes patients with visceral obesity and insulin resistance
(Guillory et al., 2017; Mykhalchyshyn et al., 2015), and also in heart
disease patients (Kilic et al., 2017). On the other hand, no correlation
could be detected between ghrelin and sarcopenia (Serra-Prat et al.,
2015), despite several studies showing a positive action of ghrelin in
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preventing decline in muscle strength and endurance (Guillory et al.,
2017). Given these contradictory results, the potential of ghrelin as a
frailty biomarker and therapeutic intervention, although promising,
needs to be further explored before a ﬁnal conclusion can be reached.
In summary, nine hormones capable of modulating the cytoske-
leton were analysed. Since hormonal changes are key modulators of
“hallmark of aging” pathways and hormones are often dysregulated in
aging and age-related diseases they can be considered highly valuable
biomarker candidates. Four candidates reached high priority scores (α-
Klotho, FGF23, FGF21, Leptin) and the other ﬁve medium scores (GH,
IGF-1, resistin, adiponectin, ghrelin).
3.7. Other principles
In this ﬁnal section we are going to discuss six additional potential
biomarkers for frailty which come from diﬀerent principles and path-
ways not covered in the previous chapters. However, most of the
markers have close relation to the hallmark of aging pathways and
could even be shifted to other chapters (see Tables 7,8, S1 and
Figs. 3–5).
We would like to note again that we focused our review on key
pathways and biomarkers measurable in bio ﬂuids and used in other
conditions. Of course, there are more pathways, factors, and markers
which could be included, such as, for example, stem cell markers or
pathways (e.g. Notch, Wnt), vitamins (e.g. vitamin D), or metabolites.
We believe that many of such additional markers are indirectly covered
as many of the markers have been shown to be interdependent and
involved in various pathways. Moreover, if frailty biomarker panels are
proven a valuable approach, optimising the power of the panel by ex-
pansion or exchanging of factors is an important next step.
miRNA (microRNA), are small non-coding RNA molecules that
function in RNA silencing and play an important role in post-tran-
scriptional regulation of gene expression. They are mostly intracellular
and regulate multiple target genes. Thus, it is not surprising that
miRNAs are key modulators of almost all physiologic processes in-
cluding tissue homeostasis and, consequently miRNA dysregulation is
seen in a variety of diseases. Actually, miRNAs speciﬁc to tissues (e.g.
muscle, for a review see (Ludwig et al., 2016), cellular functions and
dysfunction (e.g. mitochondria, apoptosis, ﬁbrosis) as well as diseases
(e.g. cancer, cardiovascular) have been identiﬁed. Moreover, with the
discovery that miRNAs circulate in cell free blood (Hunter et al., 2008),
a quest for ﬁnding miRNA based biomarkers in various body ﬂuids
including serum, plasma and even urine has begun (Razvi, 2013).
miRNAs are secreted by speciﬁc cells and subsequently taken up by
target cells to ﬁne tune gene expression (Bayraktar et al., 2017). Due to
high RNAse activity in bio ﬂuids, miRNAs are either packaged into
extracellular vesicles or bound to proteins so that they can act as hor-
mone-like molecules. Actually, packed miRNAs are surprisingly stable
in body ﬂuids and their use as biomarkers in clinical settings is an
emerging, broadly explored ﬁeld of research.
In fact, signatures of circulating miRNAs are generally explored as
diagnostic, prognostic, and therapeutic markers for a large variety of
diseases (Wang et al., 2016a; Witwer, 2015). This includes major age-
related diseases contributing to frailty, such as cancer (Hatse et al.,
2014), cardiovascular disease (Barwari et al., 2016), osteoporosis,
cardiovascular disease (Barwari et al., 2016), osteoporosis (Hackl et al.,
2016), osteoarthritis (Beyer et al., 2015), neurodegenerative diseases
(Sheinerman and Umansky, 2013), or sarcopenia (Siracusa et al., 2018).
Interestingly, miRNA signatures for predicting osteoporotic fracture
risk were even shown to have socio-economic beneﬁts (Walter et al.,
2018) and are hopefully entering clinical use in the near future.
miRNA panels seem to be especially valuable in the context of
multifactorial conditions, for which frailty is a prime example, poten-
tially complementary to single biomarker molecules in increasing de-
tection sensitivity and speciﬁcity. Ideally, such miRNA panels for frailty
should consist of tissue-, pathway- and disease-speciﬁc miRNAs (for
review see (Baker et al., 2017)). For example, tissue-speciﬁc miRNAs
are found in muscle (myomiRs) and bone (osteomiRs) and show age-
related dysregulation. Similarly, a big variety of pathway-speciﬁc
miRNAs exists for mitochondria (also known as mitomir), apoptosis,
inﬂammation, and senescence, just to name a few, as well as for dis-
eases such as cancer (also known as oncomir), cardiovascular, neuro-
degeneration, and many more. As for the other biomarkers discussed in
this review, miRNAs with broader coverage of either “hallmark of
aging” pathways or diseases would be ideal candidates such as, for
example, miRNAs associated with cellular senescence (Schraml and
Grillari, 2012; Weilner et al., 2013), inﬂammation (Olivieri et al.,
2013), or mitochondrial dysfunction (Bedreag et al., 2016). Actually,
systemic approaches to identify circulating miRNA based biomarkers
for frailty are on the way such as the OMICs approach from the FRAI-
LOMIC consortium (Erusalimsky et al., 2016; Lippi et al., 2015) and
ﬁrst results of these studies are expected to be published soon. During
completion of this review there was a ﬁrst publication available ahead
of print in the Journal of Frailty and Aging reporting enrichment of
miR-10a-3p, miR-92a-3p, miR-185-3p, miR-194-5p, miR-326, miR-532-
5p, miR-576-5p, and miR-760 in frailty (Ipson et al. 2018, ahead of
print).
To conclude, miRNA panels are emerging biomarkers in many dif-
ferent physiologic and pathophysiologic conditions and of great interest
also for frailty. Studies are ongoing to identify frailty speciﬁc miRNA
panels, already in print or discussed as scientiﬁc conferences and their
outcome will open new possibilities. We would like to mention that the
high priority score for miRNA in Table 8 is based on the broad potential
of miRNAs as biomarkers but will depend on the identiﬁcation of
miRNA panels with high speciﬁcity and predictability of frailty.
AHCY (adenosylhomocysteinase) controls intracellular AHC (S-
adenosylhomocystein) levels which are important for transmethylation
reactions and metabolic functions. It converts (AHC) to HC (homo-
cysteine) and adenosine, both molecules with broad biologic functions.
In particular increased HC levels – due to increased AHCY activity –
seem to be detrimental in many organs and were detected in neuro-
degenerative, inﬂammatory, and other diseases. For example, long-term
elevation of HC may lead to mitochondrial dysfunction, ER stress and
oxidation, apoptosis, and inﬂammation in a broad range of cell types
(Abushik et al., 2015; Hu et al., 2017; Kalani et al., 2014b) and also
accelerates senescence of endothelial cells via DNA hypomethylation of
human telomerase reverse transcriptase (Zhang et al., 2018a). Patho-
logic conditions with high HC levels are rheumatoid arthritis, particu-
larly patients with high cardiovascular risk, Alzheimer’s disease, Par-
kinson’s disease, chronic kidney disease, atherosclerosis, and elderly
patients (Derouiche et al., 2014; Haghdoost-Yazdi et al., 2014; Hu et al.,
2017; Marino et al., 2014; Motzek et al., 2016; Sun et al., 2017a; Xia
et al., 2014; Yang et al., 2015b; Ye et al., 2017b). In stroke patients,
elevated HC independently predicted severe neurological impairment,
poor functional outcome, and stroke recurrence (Shi et al., 2015b) and
is associated with long-term mortality (Shi et al., 2015b).
Full body AHCY knockout mice with increased AHC are lethal and
patients with AHCY deﬁciency also show markedly elevated plasma
AHC and primarily neuromuscular symptoms including hypotonia,
sluggishness, psychomotor delay, absent tendon reﬂexes, and delayed
myelination (Baric et al., 2005; Motzek et al., 2016). In accordance,
methionine metabolism was shown to change strikingly during aging.
Accordingly, increased AHC and tissue-speciﬁc AHC down-regulation
extended both health-span and lifespan in Drosophila (Parkhitko et al.,
2016).
AHCY is also interesting as a therapeutic target and both direct and
indirect inhibition is being pursued. For example, a few direct AHCY
enzymatic inhibitors (e.g. eritadanine, 3-Deazaneplanocin A and 9-(2-
deoxy-2-ﬂuoro-β,D-arabinofuranosyl) adenine)) or agents indirectly
reducing AHCY (e.g. folate, vitamin Bs, inﬂammasome inhibitors,
alpha-lipoic acid) exist and were shown to improve cognitive function
in elderly people, reduce HC-induced inﬂammasome activation,
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glomerular sclerosis, cell dysfunction such as ER stress and oxidation,
apoptosis and inﬂammation (Cheng et al., 2016b; Ctrnacta et al., 2010;
Hu et al., 2017; Lee and Kim, 2013; Shokar et al., 2012; Zhu et al.,
2017b).
The high priority score for AHCY is based on the fact that AHCY
dysregulation in aging and age-related diseases seems highly evident
and direct and indirect inhibition showed therapeutic eﬀects. However,
beside the enzymatic dysfunction there is evidence for accumulation of
the substrate AHC with aging which may contribute to the observed
deﬁcits. Thus, measuring substrate AHC and the product HC or maybe
building a ratio of the two measures would be the preferred way to
include AHCY in frailty biomarkers.
Microparticles, also called circulating microvesicles, are small
(0.1–1.0 μm) plasma membrane-derived extracellular vesicles present
in the bloodstream. Blood contains microparticles shed from diﬀerent
cell types, mainly platelets, but also red blood cells, granulocytes,
monocytes, lymphocytes, and endothelial cells. They may be released
during cell activation, cell injury, cell senescence, and apoptosis and
contain immunologically active molecules aﬀecting a variety of cellular
processes such as inﬂammation, coagulation, antigen presentation, and
apoptosis. Actually, microparticles can be characterised by cell surface
antigens reﬂecting their origin and activation method. Therefore, de-
termination of microparticles in plasma can be used as markers of
cellular activation or damage (for review see (Cheng et al., 2016b).
Indeed, circulating microparticles have been detected in a variety of
diseases and dysfunctions with proposed diagnostic and pathologic
function. They promote endothelial cell senescence which may be im-
portant in vascular dysfunction in aging and acute coronary syndrome
patients (Abbas et al., 2017; Burger et al., 2012). In inﬂammation,
microparticles may contribute to the pathogenesis of systemic in-
ﬂammation, autoimmune disease and sepsis (Bei et al., 2016; Blair
et al., 2016; Liu et al., 2017c). In the latter endothelial microparticles
induce an inﬂammatory response in endothelial cells, and both en-
dothelial microparticles and endothelial cells can assist in early diag-
nosis of sepsis. Moreover, bacterial infection induces platelet micro-
particles which subsequently contribute to the inﬂammatory response.
Moreover, in pulmonary arterial hypertension endothelial micro-
particles are involved in the vascular pathogenesis. Rheumatoid ar-
thritis patients, even in early stages of disease, have increased levels of
microparticles compared with healthy controls (Cunningham et al.,
2014). Patients with active rheumatoid arthritis tended to have higher
endothelial microparticles than nonactive patients. Similarly, micro-
particles are also detected in plasma of prediabetes, type 2 diabetes
patients, in chronic kidney disease, in obesity, atherosclerosis, in idio-
pathic pulmonary ﬁbrosis, various cancers and after exercise with pa-
thogenic and diagnostic action (Bacha et al., 2017; Banz et al., 2016;
Dimassi et al., 2016; Luna et al., 2016; Mege et al., 2016; Schwarz et al.,
2018; Wekesa et al., 2014). Microparticle numbers are increased in
some CNS diseases and can contribute to the onset and progression of
neurodegenerative and neuroinﬂammatory diseases, including Alzhei-
mer’s disease, traumatic brain injury, and stroke (He et al., 2017b;
Schindler et al., 2014).
Beside their potential as pathologic and diagnostic biomarkers, it
has also been suggested to directly target microparticles, particularly
their shedding and bioactivity, as a promising therapeutic strategy.
Future research will show if this is feasible and also if they can be used
as therapeutic biomarkers. To our knowledge microparticles have yet
not been measured in therapeutic intervention studies. Moreover, spe-
ciﬁc panels need to be established for “frail” patients and like for
miRNAs the score in Table 8 depends on our success in this endeavour.
KRT18 (keratin 18) is a type I cytokeratin and together with its
partner KRT8, the major type 1 keratin in epithelia found in liver,
pancreas, and intestine. Importantly, soluble fractions of KRT18 are
secreted into the extracellular space and subsequently into the blood
stream during cell death both in vitro and in vivo (Schutte et al., 2004).
In old mice, liver KRT18 is strongly upregulated and undergoes
increased phosphorylation and lysine acetylation. In addition, KRT18
expression was shown to be associated with senescence and linked to
anti-mitochondrial auto-antibody formation (Battaglia et al., 2017;
Schallmoser et al., 2010; Toivola et al., 2015). The major pathologic
action of KRT18 is on mitochondria as it modulates the shape and
function of hepatocyte mitochondria and mutation in KRT18 induces
mitochondrial fragmentation in liver-derived epithelial cells. In ac-
cordance, knock-down of KRT18 leads to an abnormal clustering of
mitochondria (Kumemura et al., 2008; Schwarz and Leube, 2016; Tao
et al., 2009) as well as enhanced apoptosis and causes predisposition to
liver injury and apoptosis (Ku et al., 1997; Mannery et al., 2011;
Marceau et al., 2001; Tao et al., 2009). KRT18 is also a known marker
of apoptosis and has been proposed as an indicator of progression in
chronic liver diseases such as non-alcoholic fatty liver disease. As
mentioned, keratins and their fragments are released into blood during
liver and other epithelial tissue injury (Ku et al., 2016). In particular the
caspase-cleaved fragment (cKRT18) is used to diagnose non-alcoholic
fatty liver disease, especially non-alcoholic steatohepatitis, to predict
development of type 2 Diabetes in non-alcoholic fatty liver disease
patients, and as novel safety biomarkers for drug-induced liver injury as
well as other liver disease and cancers. In accordance, mice with point-
mutations in KRT18 develop chronic hepatitis and hepatocyte fragility
in association with disruption of hepatocyte keratin ﬁlaments and have
an increased susceptibility to drug-induced hepatotoxicity (Kullak-
Ublick et al., 2017; Morling et al., 2014; Thulin et al., 2014). cKRT18
has potential as therapeutic biomarker and treatment with pan-caspase
inhibitors reduces cKRT18 (Yang et al., 2014). In addition, serum KRT-
18 levels are associated with 30-day mortality and could be used as a
prognostic biomarker in patients with severe traumatic brain injury
(Lorente et al., 2015).
Taken together, KRT18 and its fragment cKRT18 are highly vali-
dated biomarkers in diseases with mitochondrial and apoptotic defects
for diagnostic, prognostic, and therapeutic purpose. Such defects are
not only major “hallmarks of aging” and frailty but there is also evi-
dence that KRT18 is indeed induced with increased age and may con-
tribute to age-related diseases.
GpnmB (glycoprotein nonmetastatic melanoma B) is a membrane
protein that can be secreted as a soluble form after cleavage. It is mainly
expressed in melanocytes, osteoclasts, osteoblasts, dendritic cells,
macrophages, and overexpressed in various cancer types. Its biologic
action includes M2 macrophage polarisation, regulation of tissue re-
modelling, promoting cell migration, invasion, and metastasis. In ad-
dition, negative regulation of T-cell activation and proliferation as well
as positive regulation of the MAPK cascade have been reported. Other
biologic eﬀects of GpnmB include modulation of osteoblast diﬀer-
entiation and bone mineralisation, protection from ER stress, and a role
as a pathologic factor on mesenchymal stem cells in age-related skeletal
diseases.
GpnmB has anti-inﬂammatory and regenerative functions. For ex-
ample, in acute kidney and liver injury GpnmB promotes M2 macro-
phages polarisation and contributes to the balance between ﬁbrosis and
ﬁbrolysis (Kumagai et al., 2015). Similarly, beneﬁcial impact of GpnmB
and its signiﬁcance as a biomarker is described in non-alcoholic stea-
tohepatitis (Katayama et al., 2015) and in wound repair where it reg-
ulates cross-talk between macrophages and mesenchymal stem cells. It
has also been proposed as a novel potential therapeutic target in cancer.
Moreover, an emerging role of Gpnmb is evident in neurodegenerative
diseases. For example, GpnmB is neuroprotective in an animal model of
amyotrophic lateral sclerosis, cerebral ischemia, and other disease
models and increased brain expression is associated with risk for Par-
kinson’s disease (Budge et al., 2017; Murthy et al., 2017; Noda et al.,
2017).
Given these discoveries, GpnmB can be described as a macrophage
marker with protective eﬀects, as a prognostic marker for disease state
determination, and as direct therapeutic option in neurodegenerative
diseases and cancer (Rose et al., 2017). Since macrophages play a
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crucial role in age-associated chronic inﬂammation GpnmB is a highly
valuable biomarker candidate for frailty. GpnmB has clear potential as a
diagnostic frailty biomarker and further studies are needed to explore if
it can also be used as a therapeutic biomarker to monitor drug inter-
vention.
Lactoferrin (LTF, also known as lactotransferrin), a member of the
transferrin family, is a major iron-binding protein in milk and other
body ﬂuids. It shows antimicrobial activity and is an important com-
ponent of the non-speciﬁc immune system (Mayeur et al., 2016). It
deprives pathogens from iron, or disrupts their plasma membranes
(Drago-Serrano et al., 2017). It was also shown to reduce serum pro-
inﬂammatory cytokines, such as TNF-α and IL-6, to inhibit Treg cells
and to be involved in age-related biological processes. For example,
lactoferrin protects human mesenchymal stem cells from oxidative
stress-induced senescence and apoptosis (Park et al., 2017) and pre-
serves mitochondrial calcium homeostasis in degenerating dopamine
neurons (Rousseau et al., 2013).
Lactoferrin has potential as a biomarker for age-related neurode-
generative diseases and is, for example, upregulated in Alzheimer’s
disease. Interestingly saliva concentrations enable discrimination of
mild cognitive impairment and Alzheimer’s disease patients from a
cognitively healthy control group (Carro et al., 2017). Accordingly, in
APP-transgenic mice lactoferrin is localised in brain plaques and amy-
loid angiopathy and increased with age (Wang et al., 2010). Lactoferrin
is also increased in cerebrospinal ﬂuid of Parkinson’s disease patients
and serum TNF-α negatively correlated with both iron and lactoferrin
(Yu et al., 2013).
Lactoferrin is also used as a relevant marker to monitor metabolic
disorders. Actually, lactoferrin is inversely associated with fasting tri-
glycerides, glucose, and body composition, but directly correlates with
high density lipoprotein cholesterol (Moreno-Navarrete et al., 2008) In
contrast, insulin resistance correlates positively and independently with
plasma lactoferrin independent of adipositas (Mayeur et al., 2016). In
cardiovascular disease, plasma lactoferrin predicts the risk for cardio-
vascular events. For example, increase lactoferrin is associated with
ischemic stroke (Santos-Silva et al., 2002) and a predictor for fatal is-
chemic heart disease in diabetes mellitus type 2 patients (Vengen et al.,
2010). Moreover, functional polymorphisms in lactoferrin are related to
aortic plaques and coronary artery stenosis (Videm et al., 2012). In-
terestingly, bovine milk-derived lactoferrin exerts proangiogenic eﬀects
in response to ischemia and reduces blood pressure (Ikeda et al., 2013).
With respect to age-related inﬂammatory disorders, rheumatoid
arthritis patients have increased synovial lactoferrin which acts as
chemoattractant for both neutrophils and lymphocytes (Stanczyk et al.,
2005) and is a robust regulator of chondrocyte metabolism, comparable
to TGFβ1. Furthermore, its dual catabolic and proliferative action in
chondrocytes indicates a function as an early phase cytokine, enhancing
MMPs which are necessary for degradation of damaged tissue and
subsequent proliferation necessary for repair (Brandl et al., 2010). In
inﬂammatory disease, faecal lactoferrin is useful in the diagnosis and
management of inﬂammatory bowel diseases such as Crohn's disease
(Langhorst and Boone, 2012).
Lactoferrin is also broadly explored as a therapeutic agent. For ex-
ample, lactoferrin conjugates are tested as a new treatment for neuro-
degenerative disorders and lactoferrin is a component of new drug
delivery systems to permeate the blood brain barrier (Meng et al., 2015)
and rescue degenerative Alzheimer’s disease neurons. A combination of
Quercetin-encapsulated liposomes grafted with a bradykinin analogue
and lactoferrin has been developed (Kuo and Tsao, 2017) and similarly,
deferasirox, a high aﬃnity iron chelator, has been conjugated to lac-
toferrin (Kamalinia et al., 2013). Lactoferrin also has potential as a
therapeutic option for autoimmune and inﬂammatory diseases (Okubo
et al., 2016), and as a protecting agent against certain type of cancers
(Li et al., 2017d). For example, lactoferrin exerts anti-tumour eﬀects by
inhibiting angiogenesis and preventing migration and invasion of
cancer cells. High doses of lactoferrin inhibited cell viability in a dose-
dependent manner in a colon cancer model (Li et al., 2017d).
In summary, six biomarkers from other principles were evaluated
and showed either high priority (miRNA panel, AHCY, KRT18) or
medium priority scores (microparticle panel, lactoferrin, GpnmB). They
are valuable and important additions to the panels of frailty bio-
markers.
3.8. Published data for selected biomarker candidates in frailty
To close our analysis, we also searched for studies that tested at least
part of our proposed markers in a frail cohort. We could not ﬁnd data
for the whole biomarker panel in any one study, but several of our
selected markers appear in diﬀerent studies measuring frail, older pa-
tients. The majority of data are around inﬂammatory factors as frailty
markers and we found that changes reported for single markers across
studies were not always consistent. In the following section, a few ex-
amples are described.
One relatively well characterised cohort is the Newcastle 85+ study
and, indeed, various measures including circulating markers have been
correlated to frail or non-frail participants. At ﬁrst, inﬂammatory
markers, including IL-6 from our list, were measured and correlated to
diﬀerent frailty indices (Collerton et al., 2012; Martin-Ruiz et al.,
2011). Later on, a broader range of inﬂammation, immunosenescence
and cellular aging markers were determined, including leptin, adipo-
nectin, homocysteine and TGF-β, and cut-oﬀ points were used based on
survival curves to compose a biomarker based frailty index (Mitnitski
et al., 2015). This is a very interesting approach and similar to our
proposal as a set of markers were tested. It would be interesting to see if
the cut-oﬀs may be generally applicable and if panels are expanded to
additional “hallmark of aging” pathways. There are many other studies
measuring a few of our markers and as mentioned results are not always
consistent (Aguirre et al., 2014; Alvarez-Sanchez et al., 2018; Baylis
et al., 2013; Compte et al., 2013; Darvin et al., 2014; Gunawardene
et al., 2016; Hubbard et al., 2008a, b; Jorge-Ripper et al., 2017; Lai
et al., 2014; Lana et al., 2017; Lee et al., 2016c; Leng et al., 2002; Lu
et al., 2016; Nagasawa et al., 2018; Pacho et al., 2018; Qi et al., 2017;
Qu et al., 2009; Shardell et al., 2017; Van Epps et al., 2016; Yeap et al.,
2013).
To ﬁnally validate the usefulness of the proposed panels as well as
the advantage over single measures, further studies including mea-
surement of the whole panel of proposed markers in well-deﬁned frailty
cohorts are required.
4. Conclusion
Our search identiﬁed a variety of biomarker candidates from dif-
ferent “hallmark of aging” pathways. We propose to generate bio-
marker panels for frailty which should have higher value than single
markers. A panel of biomarkers may be more sensitive to relatively
small changes in individual markers, but collectively may reveal an
overall decline in bodily functions that may contribute to the devel-
opment of frailty and later on multimorbidity. The accumulation of
small deﬁcits may ultimately lead to a larger, more clinically relevant,
malfunction. Based on our prioritisation score we suggest a core panel
of frailty biomarkers consisting of the 19 high priority candidates: (1)
IL-6, CXCL10, CX3CL1 (2) GDF15, FNDC5, VIM, (3) regucalcin, calre-
ticulin, (4) PLAU, AGT, (5) agrin, BDNF, progranulin (6) α-klotho,
FGF23, FGF21, leptin (7) miRNA panel (to be further deﬁned), AHCY
and KRT18. An expanded panel would include the 22 medium priority
candidates (1) pentraxin, sVCAM/ICAM, defensin α (to be further de-
ﬁned), (2) APP, LDH, (3) S100B, (4) TGFβ, PAI-1, TGM2 (5) sRAGE,
HMGB1, C3/C1Q, ST2, (6) GH, IGF-1, resistin, adiponectin, ghrelin (7)
microparticle panel (to be further deﬁned), GpnmB, and lactoferrin.
Three candidates were shown to have major limitations as frailty bio-
markers and are only attributed low priority: (1) CD14, (4) MMP7,
THBS. These predicted core and expanded panels need to be
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experimentally explored in animal models and frail cohorts for vali-
dation and assessing their diagnostic, prognostic, and therapeutic po-
tential.
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